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Monoclonal antibodies specific for the porcine luteinizing 
hormone receptor (LHR) were generated primarily. to accomplish 
two major objectives: 1.) to generate antibodie.s specific for 
epitopes at or near the ligand binding do.main of the receptor, 
and 2) to determine whether monoclonal antibodies generated 
against the porcine receptor can bind to and alter the 
physiological function(s) of the human receptor. 
Several screening assays were developed to select for 
monoclonal antibodies specific f9r the receptor ligand binding 
domain. These assays include: 1) multiple types of the ELISA 
immunoassay; 2) a radiolabeled hCG competitive binding assay, to 
assess the ability of the antibody to outcompete radiolabeled 
ligand binding; and 3) a progesterone bioassay, to assess the 
ability of the antibody to alter progesterone secretion from 
cultui'ed granulosa cells. 
Based on the results of the screening procedures, a total of 
23 monoclonal cell lines were chosen for further characterization 
of both the porcine and human receptor. These studies included: 1) 
an antibody typing assay; 2) ELISA and radiolabeled hCG. 
competitive binding assays on cultured granulosa cells; 3) a 
progesterone bioassay ; 4) fluorescent microscopy studies; and 5) 
Western transfer/immunoblotting procedures. 
The results of the characterization studies indicate that 
all of the monoclonal antibodies were capable of binding to both 
t 
porcine and human cells. In addition, all of the monoclonal 
antibodies demonstrated the ability to block rc!diolabeled hCG 
binding to both porcine and human cells, and were capable of 
altering progesterone secretion from both porcine and human 
granulosa cells in culture. Interestingly, the physiological effects 
of a specific monoclonal antibody were not identical when 
comparing porcine and human assays. 
The results indicate that a significant degree of 
structural/functional similarity must exist between the ligand 
binding domains of the porcine and human LH/CG receptor. The 
monoclonal antibodies generated to the porcine LH/CG receptor 
should prove very useful in helping not only to define the 
structure and activational mechanisms of the porcine LH/CG 
receptor, but the human receptor as well. 
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A wide variety of the metabolic processes in the ovary are 
reguiated by the pituitary luteinizing hormone (LH). These include, 
follicular development, oocyte maturation, ovulation, formation 
and maintenance of the corpus luteum, as well as steroid· 
pr(;duction. LH regulates these events through the interaction of a 
specific membrane bound receptor, the luteinizing 
hormone/chorionic gonadotrcpin receptor, (LH/CG R) located 
primarily on the granulosa cells of the ovary. 1 
One well documented response of target cells to the 
binding of luteinizing hormone (LH) or chorionic gonadotropin (CG) 
to its specific membrane bound receptor is an . . increase 1n 
adenylate cyclase activity mediated by an intracellular 
membrane- associated G protein. The resulting . increase 1n 
adenosine 3', 5'-monophosphate, (cyclic AMP), ultimately leads to 
an increase in steroid synthesis and secretion.2 
The mammalian LH/CG receptor is a member of the 
G-protein coupled receptor family. 3 Complementary DNA anaylsis 
of the rat receptor reveals: 1) a 26 amino acid signal peptide, 2) 
an extensive extracellular domain of 341 amino acids, (360 amino 
acids in the porcine receptor, and 365 amino acids in the -human 
receptor) 2 3 ,which contains 6 potential sites of N-linked 
glycosylation that are -well conserved among known mammalian 
species and are believed to be critical for ligand binding, 3) a 333 
3 
amino acid domain containing 7 transmembrane segments, which 
displ·ay sequence homology to all members of the G 
protein-coupled receptor family and, 4} an in_tracellular 
COOH-ter·minal domain of approximately 68 amino acid residues 
which contain potential phosphorylation sites, (serine, threo.n.ine, 
and tyrosine), where cellular control of receptor activity may 
occur. 3 
A family of G p ro·tei n-cou p.led receptors has been 
identi"fied whose members are characterized by the common 
structural feature of seven transmembrane domains known to be 
involved in signal transduction and in the binding of s_mall 
I igands. 4 The extensive extracellular domain of the LH/CG 
receptor, however, is in direct contrast to other members of the G 
pro t e i n -co u p I e d rec e pt o r fa m i I y , s u c. h as th e s .e rot o n i n o r 
acetylcho·lin_e receptor, which contain relatively· smaller 
extracellular domains. 5 Presumably, the large extracellular 
domain of the LH/CG receptor is to facilitate the binding of its 
ligands, LH and CG, which are among the largest mammalian 
glycoprotein hormones known, having molecular weights of 28.5 
kDa and 40 kDa, respectively. 5 
In addition to the relatively large size of the extracellular 
domain, cDNA sequence analysis of the extracellular domain of the 
rat -LH/CG receptor has tu rther revealed several significant 
sequence features, the most striking of which is a 14-fold 
imperfectly repeated sequ-ence of approximately 25 amino acid 
residues. Similiar motifs, termed leucine-rich repeats have been 
4 
recognized in various -proteins compr1s1ng the family of leucine 
-rich g 1. y cop rote ins , (LR G) . 6 Me ·m be rs of LR G fa mi I y have been 
postulated to interact with both hydrophobic and hydrophilic 
surfaces, possibly mediatec by amphipathic helices formed by the 
r·e peat st r u ct u res . S i n c e th e I a r g e extra c e II u I a r do m a i n of the 
LH/CG receptor is apparently responsible for the bindi.ng of LH and 
CG, this domain may be responsible for both the binding of 
hormone and for interacting with the transmembrane domains to 
mediate signal transduction. 5 , 7 
A-n other u n i q u e feat u re with i n the extra ce II u I a r do ma i n of 
this receptor constitu.tes a site defined by 1 O amino acid residues 
that are identical to a sequence present 1n soybean lectin, 8 and is 
believed to play a significant role 1n the b·inding of the 
glycosylated form of the ligand, and the activation of the 
intracellular secondary messengers. Although deglycosylated LH 
and CG bind to the receptor with high affinity,. this interaction 
results in little or no stimulation of adenylate cyclase, 9 hence 
this site may be involved in the recognition of the glycosylated 
hormone and the functio-nal co·upling of the receptor .to Gs, 
maximally achieved only with the glycosylated forms of LH and CG. 
Progress toward the elucidation of the structure of the 
LH/CG receptor has been hampered. by the low abundance of this 
receptor in ovarian tissue, 1 o, 11 (i.e large quantities of ovarian 
tissue are required for the isolation of only a few m·icrograms of 
purified receptor); and its susceptibility to proteolysis 1. 2 , 13 , 14 
and conformational denaturation, resulting 1n a significant loss of. 
5 
ligand binding activity. 15 
Advances in recent years, incl.uding modifications of the 
pu rificatiori technique such as the addition of E OT A, a fu 11. 
spectrum of protease inhibitors, and 25°/o glycerol to preserve 
binding activity, have made it possible to purify the intact/ 
functional receptor in quantities s uff icien t for characterization 
studies, 13, 14 , 15 in particular the productiq n of antibodies specific 
for this receptor. In recent years, there have been few reports in 
the literature of antibodies produced against this 
r e c e p t o r . 1 6 · 1 7 · 1 8 · 1 9 · 2 0 · 2 1 T h es e p u b I i cat i o n s h ave i n c I u de d 
antibodies primarily produced against the rat receptor 1 6 · 
17
, 18 , 19 ,20 and have been almost exclusively poly·clonal in nature, 
produced in response to injecti.ons of crude .ovarian membrane 
preps. 16, 17 , 19 ,20 Monoclonal antibodies, however, would be superior 
to conventional antisera for a detailed characterization of the 
structure/function of this receptor for the following reasons: 22 1) 
they are directed against a single epitope (antigenic determinant); 
2) they are homogeneous with respect to affinity and specificity; 
3) hybrid.oma cell lines can be cultured for a continual supply of 
well-defined antibody and/or be frozen for future use; and perhaps 
most significantly, 4) monoc.lonal antibodies can be "tailor made". 
22 
The primary goal of th is 'resea.rch was to prod uc~ 
monoclonal antib.odies specific for epitopes at or near the ligand 
binding do1nain of the porci.ne LH/CG receptor, as it is believed 
these would be physiologically most significant. 
6 
Multiple screening assays were developed ·to select for 
monoclonal antiboaies which demonstrate key functional 
properties. These included: 1) the ability to competitively block 
the binding of radiolabeled hCG to the receptor, and 2) the ability 
to alter progesterone secreticn from porcine gran ulos~ cells in 
culture. 
An additional goal o.f this research was to determine the 
cross reactivity of these antihodies to the human LH/CG receptor 
through the use of novel characterization assays. As cDNA 
sequence anaylsis of the porcine and human receptor reveals a 
grea:er than 94°/o homology, 23 a significant degree of 
cross,..reactivity was expected. 
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A. Isolation and Purification of the LH/CG Receptor 
Corpora luteal tissue was excised from porcine ovaries 
(·obtained from the slaugterhouse in Hatfield, Pa.) and homogenized 
in the presence of multiple protease inhibitors. The membrane 
extract was solubilized and- incubated with hCG bound Sepharex 
beads overnight at 4'C, to allow sufficient binding of the LH/CG 
receptor ·to the hCG. The LH/CG receptor was then eluted from the 
beads with an ac_idic (pH 4.0) wash buffer, using an affinity 
ch ro mt og rap h i c procedure. The e I u ted s amp I e, containing purified 
LH/CG receptor, was concentrated to a volume of approximately 
5-1 O mis and dialyzed against PBS and then distilled water, to 
remove excess salts. 
(For a more comprehensive description of procedures used 
1n the purification of the LH/CG receptor see Appendix A). 
B. Immunization protocol: 
Female Balb/C mice, were injected either intradermally or 
intraperitoneally with 1 of 3 different innoculations: 1) purified 
LH receptor, 2) membrane vesicles or 3) hCG. 
Pur.i.fied LH receptor is the antigen of choice for 
innoculation procedures, however, it is difficult to .obtain 
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sufficient quantities for the innbculation of multiple an.imals and 
subsequent boosts every 3-4 weeks. In addition, the puri'ied 
receptor is susceptible to conformational denaturation and 
proteolytic degradation. For these reasons, corpora luteal 
membrane vesicles were also used for innoculations in order to 
ensure both sufficient quantities of LH/CG receptor prot.ei·n· for 
innoculation 
conformation. 
and also that the 
. . . 1mmunogen 1s 1n its native 
Additionally, human chorionic gonadotropin, (hCG) was 
used in the immunization protocol to develop anti-idiotypic 
antibodies, as anti-idiotypic antibodies specifiG fo ( the hCG 
binding site may be equivalent to antibodies specific for the 
bindi.ng site of the LH/CG receptor. 
All innoculations were given as a low dose, 
antigen /adj u van t comp I ex. P r i mar y i. n j e ct ions were g Ive n I n 
Complete Freund's adjuvant (Sigma), while subsequent boost 
injections, every 3-4 weeks, were given in either Incomplete 
Freund's adjuvant, (Sigma), or Adjuvax, ( Alpha-Beta Technology, 
Worcester, MA.), in order to c.ompare their effectiveness.. There 
~ppeared to be no significant difference in the adjuvants used; 
(data not presented), although Adjuvax was easier to prepare and 
inject. 
The immunization protocol is outlined in detail in Table 1. 
The data for each injection performed includes: the date of the 
innoculation, the identificatio.n of the mouse,. (group and number 
based on left and right ear punctures, respectfully), the protein 
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Table 1: Protocol for the Immunization of Female Balb/C Mice. 
The abbreviations used in the table are as follows: CV= coated vessicles, MV= 
membrane vessicles, LHR= Luteinizing Hormone receptor, pLH= procine LH, hCG= 
human chorionic gonadotropin, CP= Cyclophosphamide, CF= Complete Freund's 
Adjuvant, IF= Incomplete Freund's Adjuvant, AD= Adjuvax, ID= lntradermal, IP= 
lntraperitoneal, IS= lntrasplenic, IV= Intravenous, ug=microgram, ul=microliter 
-----------------------------------------------------
Group Number Date lmmunogen Protein Volume Injection Adjuvant 
----------------------------------------------------------
A 1 3/17/90 CV 35 ug 100 ul ID CF 
4/24/90 CV 20 ug 100 ul ID IF 
5/30/90 CV 20 ug 100 ul ID IF 
7/16/90 ()J 20 ug 100 ul ID IF/AD 
9/8/90 ()J 20 ug 100 ul ID AD 
9/25/90 ()J 30 ug 100 ul ID AD 
10/12/90 ()J 30 ug 100 ul ID AD 
2 3/17/90 MV 200 ug 100 ul ID CF 
4/24/90 MV 50 ug 100 ul ID IF 
5/30/90 MV 50 ug 100 ul ID IF 
6/ 3·019 0 MV 50 ug 100 ul· ID AD 
7/16/90 MV 50 ug 100 ul ID IF/AD 
9/8/90 MV 100 ug 100 ul ID AD 
9/25/90 MV 50 ug 100 ul ID AD 
10/12/90 MV 50 ug 100 ul ID AD 
3 3/17/90 MV 200 ug 100 ul ID CF 
4/24/90 MV 50 ug 100 ul ID IF 
5/30/90 MV 50 ug 100 ul ID IF 
6/25/90 MV 50 ug 100 ul ID AD 
7/16/90 MV 50 ug 100 ul ID IF/AD 
9/8/90 MV 100 ug 100 ul ID AD 
9/25/90 MV 50 ug too ul ID AD 
10/12/90 MV 50 ug 100 ul ID AD 
DIED 
4 4 I 2 4 /.9 0 L.HR 10 UQ· 100 ul ID CF 
5/30/90 L.HR 1 o ug 150 ul ID IF 
6/25/90 L.HR 10 ug· 100 ul ID IF 
7/16/90 L.HR 10 ug 100 ul ID IF/AD 
9/8/90 LHR 10 ug 100 ul ID AD 
9/25/90 MV 50 ug 100 ul ID AD 
~ 0/12/90 MV 50 ug 100 ul ID AD 
-------------------------------------------------
10 
(Table 1 continued) 
. 
. 
. 
B 1 3/17/90 till 40 ug 100 ul ID CF 
4/24/90 till 10 ug 100 ul ID IF 
5/30/90 tffi 10 ug 100 ul ID IF 
7/16/90 tffi 10 ug 100 ul ID AD 
9/8/90 hCG-8 13 ug 100 ul ID AD 
9/25/90 hCG-8 15 ug 100 ul ID AD 
2/12/90 MV 100 ug 100 ul ID AD 
2 3/17/90 40 ug 100 ul ID CF 
DI.ED 
3 ~/17/90 hCG-8 40 ug 100 ul ID CF 
4/24/90 hCG-8 10 ug 50 ul ID IF· 
5/30/90 hCG-8 10 ug 100 ul ID IF 
7/16/90 hCG-8 10 ug 100 ul ID AD 
9/8/90 hCG-B 13 ug 100 ul ID AD 
9/25/90 hCG-8 15 ug 100 ul ID AD 
10/12/90 pLH 15 ug 100 ul ID AD 
FUSION 
4 3/17/90 hCG-8 40 ug 100 ul ID CF 
4/24/90 hCG-8 10 ug 50 ul ID IF 
5/30/90 hCG-8 10 ug 100 ul ID IF 
7/16/90 hCG-8 10 ug 100 ul ID AD 
9/8/90 hCG-B 13 ug 100 ul ID AD 
9/25/90 hCG-8 15 ug 100 ul ID AD 
10/12/90 pLH 15 ug 100 ul ID AD 
E 1 3/31I90 till 0.5 mg 500 ul IP saline 
4/1 /90 CF 3.18 mg 250 ul IP saline 
4/16/90 till 40 ug 40 ul IS saline 
5/ 3.019 0 MV 200 ug 500 ul IP IF 
6/25/90 LHR 20 ug 250 ul IP AD 
7/16/90 LHR 40 ug 25·0 ul IP IF/AD 
9/8/90 LHR 10 ug 100 ul ID AD 
9/25/90 MV 50 ug 100 u.l ID AD 
10/12/90 MV 50 ug 100 ul ID AD 
FUSION 
2 3/17/90 till 1.0 mg 500 ul IP CF 
4/1 /90 CF 3.18 mg 250 ul 1p· saline 
4/16/90 till 40 ug 40 ul IS saline 
FUSION 
-------------------------------------------------------------
1.1 
(Table 1 continued) 
--------------------------------------------------'-.------.---------
3 3/17/90 till 0.4 mg 400 ul IP saline 
3/17/90 till 25 ug 150 ul ID CF 
4/1 /90 CP 3.18 mg 250 ul IP saline 
4/16/90 till 40 ug 40 ul IS saline 
FUSION 
4 3/17/90 LHR 15 ug 100 ul ID CF 
4/24/90 LHR 10 ug 100 ul ID IF 
5/30/90 LHR 10 ug 150 ul ID IF 
6/25/90 LHR 10 ug 100 ul ID AD 
7/16/90 LHR 50 ug 100 ul IV saline 
7/16/90 LHR 20 ug 300 ul. IP AD 
FUSION 
F 1 9/8/90 till 1S ug 100 ul ID AD 
9/25/90 till 15 ug 100 ul ID AD 
10/12/90 pLH 20 ug 100 ul ID AD 
2 9/8/90 till 100 UQ' 500 ul IP AD 
9/25/90 MV 100 ug 500 ul IP AD 
10/12/90 pLH 2.0 ug 100 ul ID AD 
3 9/8/90 till 500 ug 500 ul IP AD 
9/9/90 CP 3.177 mg 250 ul IP saline 
9/ 2 5/ 9 0 till 500 ug 500 ul IP AD 
1. 0/12/90 MV 100 ug 500 ul IP AD 
. 
. . 
-------------------------------------------------------------
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used as the immunogen, the micrograms of protein injected, the 
total volume of the injection, the type of injection performed, and 
the specific adjuvant used. 
At regular intervals during the immunization procedure a 
blood sample was taken from each of the immunized mice to 
determine serum anti-LH/CG receptor antibody titer. Each of the 
immunized mice was bled from the capillary bed of the eye, using 
a filed nine inch glass pipette. The average amount of blood 
withdrawn per bleed was 0.2-0.4 mis. 
Serum anti- LH/CG receptor antibody· titer, measured by 
ELISA and radiolabeled hCG competitve binding assays, (to be 
defined later), established the selection criteria .of mice to be 
sacrificed and used for splenocyte:myeloma cell fusion procedures. 
Three to four days before fusion an intrasplenic injection 
was performed on the selected mouse to maximize the clonal 
expansion of the antigen specifc cell lines. In brief, the animal 
was anesthetized, the left side of the abdomen shaved and the skin 
cleaned with alcohol. A small incision was made in the abdominal 
wall. The spleen was gently extended outside of the body using 
sterile forceps, and injected lengthwise with purified LH/CG 
receptor, 10 ug total protein, using a 1 cc sterile syringe fitted 
with a 28g needle. The spleen was then inserted back into the 
abdominal cavity. Sutures were carefully clamped in place and the 
animal was allowed to recover. 
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c. Somatic Cell Hybridization (cell fusion) 
A polyethylene glycol fusion procedure was performed 
according to the method described by Arthur and Massey. 2 2 
Following the fusion procedure, the cells were resuspended 1n 
growth media, in a total volume proportional to the number of 
spleen cells used for the fusio.n, (i.e. 10 mis. per every 10-15 
million spleen cells), and plated out in 96-well plates,(100 
ul/well). Cell cultures were grown- 1n lscove's Modified Delbecco's 
media containing 10°/o Fetal Bovine Sera (FBS) and 
hypoxanthine-aminopterin- thymidine (HAT) for approximately 
7-10 days for the selection of hybridomas. When the cell growth 
reached half to full confluency, screening procedures to- select for 
hybridomas producing antibodies to the LH/CG receptor began. 
( A detailed description of the fusion procedure and 
selection of hybridomas in HAT-containig media is provided in 
Appendix B); 
o. Screening Technigues 
Hybridoma culture supernatants were screened in two 
Phases: 
In Phase 1, two specific techniques were used. The ELISA 
immunoassay procedure, to detect and quantitate lgG antibodies to 
the LH/CG receptor, and a radiolabeled hCG competitive binding 
assay, to detect antibodies which have the ability to outcompete 
14 
radiolabeled ligand binding to the receptor
. Clones which 
demonstrated the highest .titer to the LH/CG recep
tor in the ELl·SA 
immunoassay and the greatest degree of inhibitio
n of radiolabeled 
hCG binding were chosen for subcloning by limitin
g dilution to 
establish monoclonal cell lines. 
In Phase 2, the ELISA and hCG inhibition assays were 
repeated on all monoclonal cell lines.; 1n additio
n, a bioassay was 
performed to select for antibodies which have 
the abil.ity to alter 
progesterone secretion from. porcine g-ranulo.sa ce
lls in culture. 
The protocols for assay development are o
utlined 1n 
greater detail in the Appendix C of this writing an
d are, in brief: 
a) The Enzyme-Linked-lmmunosorbent Assay (ELISA) 
The ELISA technique was performed accordin
g to the 
method of Arthur and Massey, 
22 with the following mod_ifications: 
1) 96-well polystyrene microtiter plates (Corning-, Inc.) we
re 
coated with 1 of 3 different types of antigen 
including purified 
LH/CG receptor, membrane vesicles, or purified m
ouse lgG for the 
quantitation of lgG in the culture supernantant, 
determined from 
known standard concentrations of mouse lgG ru
n in parallel with 
the assay; 2) 1 o/o BSA/PBS was used as the blocking agent; 3
) goat 
anti-mou$e lgG-Horse Radish Peroxidase (HAP) (Zymed, Inc., S
o.San 
Francisco, Ca.) was used as the secondary antibody com
plex, 
(1 :2000 dilution in 2°/o BSA/PBS); 3) 2-2'-Azin
o-bis 
(3-ethyJbenzthiazoline-6-)sulfonic acid, (ABTS) (Sigma), wa
s the 
substrate used and. the absorbance values were r
ead at 405 .nm.; 4) 
15 
all incubations were at 37'C for 1 hour; 5) PBS/0.05°/o Tween-20 
was used for all washing steps. 
b) Radiolabeled-labeled hCG Competitive Binding Assay 
Th is assay was specifically developed to detect antibodies 
which have the ability to competitively inhibit radiolabeled ligand 
binding to the receptor. In brief,. hybridoma culture supernatant 
was added to individual wells of a 96-well microtiter plate 
containing porcine corpora luteal membrane vesicles. The plates 
were incubated at 37'C for 2 ho·urs. Radiolabeled hCG 
(100,000-200,000 cpm at 35 cpm/ng protein) was added to each 
well and the assay plate was further incubated at 37'C for 3 hours. 
The contents of each well were removed to a microtiter plate 
containing pores on the bottom of each well but lined with a fi.lter 
.paper disc. Each well was extensively washed to remove residual 
unbound radi'olabeled hCG. The total radioactivity from each well 
was counted in the gamma .counter, (Beckman Gamma 5500) and 
was indirectly proportional to the degree of inhibition caused by 
the antibody. 
(A detailed description of the procedure followed for the 
·iodination of hCG i's provided in Appendix E.) 
c) In vitro Progesterone Bioassay 
Porcine granulosa cells were isolated ·trom ovarian 
follicles, and cultured in microtiter plates, changing the culture 
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media every 2 days until the cell density reached near confluency, 
about 7-1 O days. Each monoclonal antibody was added, in 
duplicate, to· the culture media of individual wells and incubated 
for 2 hours. To one of each pair of monoclonal antibody cultures, 
hCG was added. To the other, media alone was added. At timed-
intervals, (i.e. 2 hours, 4 hours, and 12 hours), a sample from each 
of the wells was removed into a sterile 96-well plate and frozen 
at -20'C until a progesterone Rl·A procedure was performed, 
(Coat-a-Count kit, Diagnostic Products Corporation, Los Angeles, 
CA). 
Selected monoclonal cell lines were propagated in cell 
culture using 25-ml flasks. In addition, concentrated cell cultures 
were per.itoneally injected into Balb/C mice for ascites 
production. The ascites production proved to be more effective, as 
the antibody concentration was typically in the range of 5 mg/ml. 
In contrast, cell culture methods produced antibodies 1n 
one-hundredth to one-thousandth the concentration. 
o. Characterization of the Selected Monoclonal Antibodies 
Selected monoclonal antibodies, 23 in total, were further 
characterized using several assays, including: an antibody typing 
assay to determine the lgG subclass as well as ELISA 
immunoassays, radiolabeled competitive binding assays and 
fluorescent microscopy studies on cultured porcine and human 
granulosa cells. The importance of these cellular assays was to 
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ascertain the ability of a specific monoclonal antibody to bind to 
and influence the. biological activity of the receptor on viable 
cells in culture. Thi.s is 1n contrast to the ELISA and hCG 
competitive binding assays performed during the initial series of 
screening procedures, which primarily used corpo.ra luteal 
membrane vesic.les. The LH/CG receptors on cultured, luteinized 
cell's are presumed to be in a biologically potent conformatron, 
which cannot be guaranteed when using membrane vesicles or 
purified LH/CG receptor. In addition, Western Transfer/ 
immunoblot procedures were included in the characterization 
studies and were performed on both porcine and human ovarian 
membrane extracts to demonstrate the binding of the monoclonal 
antibodies to the isolated receptor protein band. 
In contrast to the screening assays performed on culture 
supernatants, all characterization studies were perfotmed using 
ascites fluid, with the exception of monoclonal antibody 6F11 AS 
(#73), since this mouse died in the process of ascites production. 
The procedures used for characterization studies are 
extensively outlined in Appendix D and are , in brief: 
a. Antibody Typing Assay 
An ELISA immunoassay was performed according to the 
method of Arthur and Massey,22 to determine the lgG subclass of 
each of the monoclonal antibodies. The following modifications 
were made: 1) ELISA microtiter plates (Corning, Inc.) were coated 
with goat anti-mouse lgG antibody, gamma chain specific, ( Zymed, 
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Inc., So. San Francisco Ca., catalog # 62-6600); 2) 1°/o BSA/PBS 
was used as the blocking agent; 3) four types of secondary 
antibody conjugates were used in order to differentiate lgG 
subclass.. These included rabbit anti-mouse lgG 1 /a I ka Ii n e 
phosphatase, rabbit anti-mouse lgG2a/alkaline phosphatase, rabbit 
anti-mouse lgG2b/alkaline phosphatase, and rabbit anti-mouse 
lg.G 3/alkaline phosphatase; 4) the substrate used was n-para 
Nitrophenyl Phosphate, Sigma catalog # N-9389) and absorbance 
values were monitored at 405 nm. and 5) all incubations were 1 
hour at 37'C; and 6) PBS/0.05°/o tween-20 was used for all washing 
steps. 
b. Granulosa Cellular ELISA 
Porcine and human granulosa cells were grown 1n separate 
96-well microtiter plates in CMPOC media, changing th.e media 
every 2 days until the cell density reached near confluency, about 
7-10 days. 
The media from each well was aspirated and replaced with 
a 1 :5'0 dilution of specific antibody in HBSS/1 °/o BSA, (100 
ul/well). The cell cultures were incubated at 37'C for 1-1.5 hours. 
All wells were washed 3-4 times with HBSS/1 °/o BSA, (250 
ul/well/wash). 
Goat anti-·mouse lgG/8-galactosidase secondary antibody 
conjugate, (1 :200 dilution in HBSS/1 o/o BSA), was added to all 
wells, (100 ul/well), and incubated at 37'C for 1-1.5 hours. 
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All wells were washed as described above. 
The substrate, 4-me.thylumbilleryl B-D-galactoside 
(Sigma) in Tris buffer, (1 mg. dissolved in 1 ml DMSO then added to 
24 mis. Tris buffer), was added to all wells, (125 ul/well), and 
incubated at 37'C for 30 minutes. 100 ul/well supernatant was 
removed and transferred to a black fluorescent ELISA microtiter 
plate and an equal volume of 1 M glycine, pH 10.0, was added to 
each well to stop the reaction. 
The absorbance values were .read in a Fluoroskan II, 
fluorescent ELISA plate reader, (Flow Laboratories, Inc., McLean , 
Virginia) at a excitation wavelength of 355 nanometers and an 
em1ss1on wavelength of 460 nanometers. 
c. Granulosa Cell Radiolabeled hCG Competition Assay 
Porcine and human granulosa cells were grown in separate 
96-well plates in CMPOC media, a described for the cellular ELISA 
assay. When the cell density reached near confluency, the media 
was aspirated from each well and replaced with a 1 :25 dilution of 
specific antibody in HBSS/1 °/o BSA, (100 ul/well). The "total 
binding" control wells received only media and the "non-specific" 
control wells received media plus excess cold hCG. 
The cell cultures were incubated at 37'C for 2 hours. 
Radiolabeled hCG was added t6 all wells, (200,000 
counts/SO ul), and cell cultures were incubated for 3 hours. 
All wells were washed gently 3-4 times with HBSS/1 °/o 
BSA, (200 ul/well/wash). 
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50 ul/well of distille-d water, followed by 50 u I of 2N 
NaOH was adde.d to each well. The contents of each well was 
absorbed into cotton swabs, placed into 12 X 75 glass tubes and 
counted for total radioactivity in the gamma counter, (Beckman 
Gamma 5500). 
d. fluorescent Microscopy 
Porcine and human granulosa cells were grown on separate 
8-chamber microscope slides, in a total volume 400ul CMPOC 
media /chamber. The media was replaced every 2 days until the 
cell density reached 50°/o confluency, about 7-10 days. 
Specific antibody dilutions were added to ind·ividual 
chambers, (1 :50 dilution; total volume/chamber 400ul). Slides 
were incubated at 4'C overnight in a gassed, sealed container to 
minimize internalization of the antibody/receptor complexes. 
Prior to assay, slides were incubated at 37'C for 1 hour in order to 
assure maximum binding. 
Chambers were washed 3 times with HBSS/1 °/o BSA, (250 
ul/well/wash), to remove excess unbound antibody. 
Anti-mouse lgG TRITC conjugate, (Sigma), (1 :200 dilution 
1n HBSS/1 °/o BSA) was added to all wells, (250 ul/well). 
Slides were incubated at room temperature for 4 hours in 
a sealed, gassed contai'ler and the chambers were washed as 
described above. 
-\ 
Cell culture media was added to each well prior to 
observation under the fluorescent microscope, (Olympus BH2 
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Epifluorescent Microscope). 
e. EI e ct ro Pb ores is/Wester o T ra o sf er/ I mm u o ob Io t 
Porcine corpora luteal tissue was processed as described 
previously for the isolation of purified LH/CG receptor. 
(See 
Appendix A). This membrane extract was frozen at -?O'C in 3 ml. 
alloquots to be used for repeated electrophoresis procedures, 
as I 
found that in order to preserve intact receptors with significa
nt 
binding capacity, it was critical to us.e solubilized membrane 
prep 
which had not been thawed and refrozen. 30-SOug of protei
n/gel 
was run in a -mini-gel electrophoresis apparatus, (Hoefer 
Scientific Instruments, San Fransisco, Ca.), under non-reducing 
conditions. A mixed standard consisting of: myo
s1n, 
B-galactosidase, phospholipase b, albumin, and carbonic anhyd
rase 
was run in parallel with the membrane protein on each gel. 
Subsequent to the electrophoresis procedure, Western 
transfer to S&SNC paper, (Schleider and Schuell, Inc., Keene, NH.} 
was performed using an LKB 2117 Multiphor II Electropho
resis 
system, (LKB ·Produkter AB, Bromma, Sweden), at 50v , 56mAmps 
for 2.5 hours. 
Upon disassembly of the transfer unit, the standard lane 
as well as an adjacent membrane protein lane was cut, washed 
with PBS, then distilled water and put in Aurodye for resolutio
n of 
the protein. bands. An immunoblot procedure, using a Miniblo
t 16 
apparatus, (lmmunetics, Cambridge, MA.), was performed on the 
rema1n1ng nitrocellulose filter ·paper, using the 23 monoc
lonal 
antibodies selected during the screening process. 
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A; Immunization 
ELISA immunoassays and radiolabeled hCG competitive 
binding assays were performed on immunized mouse sera at 6 
weeks, 10 weeks and 18 weeks after primary injection. The 
results of these assays are summarized in Tables 2, 3, and 4, 
respectively. On 6/6/90, (Table 2), mice A2, A3 and E4 
demonstrated antibody titers greater than 1 :3200 in the membrane 
Ve s i CI e ( M V) EL I s A i mm u n Oas say, with 5 7 °/o' 5 5 °/o and > 1 1 2 °/o 
inhibition of radiolabeled hCG binding, respectively. Mouse A4 
demonstrated a serum antibody titer of 1 :800 in the MV ELISA 
immunoassay, however a 109°/o inhibition in the hCG competitive 
binding assay. Mouse E1 showed the lowest titer in the MV ELISA , 
with a v a I u e of < 1 :1 0 0, despite a 7 4 °/o inhibition of radio I a be I e d 
h CG binding . 0 n 7 / 5/9 0, (Tab I e 3) , all of the mice inc I u ding E 1 , 
demonstrated significantly increased antibody titer in the MV 
ELISA immunoassay, serum values ranging from 1 :75,000 for 
mouse E1 to 1 :800,000 for mouse E4. Interestingly, all of the mice 
showed significantly increased concentrations of serum lgG, (all > 
_80 mg/ml), versus lgM, (serum values ranging from 0.51 mg/ml for 
mouse E1 to 0.85 mg/ml for mouse A4), possibly indicating the 
secondary phase of an immune response to the injected antigens. 
On 10/1 /90, (Table 4), the antibody. titer of mice A3, A4, and E1 
declined slightly in the membrane vesicle ELISA immunoassay 
23 
Table 2 : Serum Anti-LHR Titer of the lnnoculated Mice on 6/6/90 
Date of BI eed M o use 
6/6/90 A2 
A3 
A4 
E1 
E4 
ELISA 
(titer) 
> 1: 3200 
> 1: 3200 
1: 800 
< 1: 100 
> 1: 3200 
24 
*hCG Inhibition 
( 0/o inhibition) 
57 
55 
109 
74 
>112 
Table 3: Ser"um Anti-LHR Titer of the lnnoculated Mice o
n 7/5/90 
Mouse 
lgG 
ELISA 
(titer) 
lgM MV 
hCG Inhibition 
( 0/o inhibition) 
----
----
----
----
----
----
----
----
----
----
----
----
----
--
7/5/90 A2 >80 mg/ml 0.78 m
g/ml 1: 250,000 0 
A3 >80 mg/ml 0.69 mg/ml 1: 100
,000 40 
A4 >80 mg/ml 0.85 mg/ml 1: 400,0
00 29 
E1 >80 mg/ml 0.51 mg/ml 1 : 75,00
0 19 
E4 >80 mg/ml 0.64 mg/ml 1: 800,00
0 58 
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Table 4: Serum Anti-LHR Titer of the lnnoculated Mice on 10/1 /90 
-------------------------------------------------------------
D1t~ Mou1~ ELISA *bCG labibition PEG gr~~i~ 
( 0/o inhibition) (anti-hCG 
LHR MV lgG Abs) 
-----------------------------------------------------
10/1/90 A1 1 : 500 1: 62,500 >80 mg/ml 12 .6 161. 7 
A2 1: 2500 1 :300,000 >80 mg/ml 21 .2 133.1 
A3 1 : 500 1: 50,000 >80 mg/ml 26.2 248.5 
A4 1: 5000 1 :300,000 >80 mg/ml 81 .6 201 9. 0 
E1 1: 2500 1: 30,000 >80 mg/ml 56 .1 1476.4 
F1 1 : 50 1: 500 >80 mg/ml 22.5 197.2 
F2 1 : 50 1: 2500 75 ug/ml 78 .1 2375.2 
F3 1 . . . 400 1 :75 40 ug/ml -88.2 2483. 7 
81 1 : 500 1 :500 >80 mg/ml 27.6 710.4 
B3 1.: 600 1 :600. >80 mg/ml 24.3 877.9 
84 1 : 500 1 :500 >80 mg/ml 31. 9 433.1 
G2 1 : 500 1 :300,000 125 ug/ml 51.5 2421.8 
G3 1: 400 1 :400 255 ug/ml 70.9 1895.4 
------.-------------------------------------------------------. . 
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(MV), from 1: 100,000 to 1 :50 ,000; 1 :400 ,000 to 1 :300 ,000; and 
1 :75,00 to 1 :30,000 , respectively. This may indicate that the 
secondary immune response had dropped and boost injections were 
needed. The total serum lgG concentrations, however, all remained 
consistently high, (>80mg/ml). The mic.e in groups F and G were 
given primary injections on 9/8/90,. and were included in the 
collection of blood samples on 10/1 /90. All of these mice, with 
the exception of G2, showed significantly lower antibody titer in 
the MV ELISA immu·noassay, values ranging from 1 :75 for mouse F3 
to 1 :2500 for mouse F2. These results were expected since the 
primary injections had been given only 3 weeks prior to the 
bleeding. 
This data was used as the selection criteria for mice to 
be sacrificed· and used for sprenocyte:myeloma cell fusion 
procedures. The first 2 fusions were performed on 4/19/90, 2 
weeks after primary injection, therefore no seru·m values were 
obtained from these mice. The serum from mouse E4, however, 
consistently showed the highest serum titer in the ELI SA 
immunoassays,(>1 :3200 and 1 :800,000) and demonstrated the 
greatest percentage of inhibition in the hCG competitive binding 
assays, (>112°/o and 58°/o), and therefore was sacrificed and used 
for the third fusion procedure .on 7/20/90. The fourth fusion, was 
performed on 10/17/90 for the purpose of produ·cing 
anti-idiotypic .antibodies. Since all of the mice in group 'B' had 
only received injections of hCG, yet demonstrated serum antibody 
titer tq the LH/CG receptor, these provided excellent candidates. 
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Of this group, m9use 83 demonstrated the highest antibody titer in 
the ELISA immunoassays, (1 :600), and so was sacrificed and used 
in the fusion procedure. 
B: Fusion Procedures and Initial Screenings 
The data from the 4 fusions performed is summarized in 
Table 5 . The identification of the mouse sacrificed for the fusion, 
the date of the procedure, as well as the number of spleen cells· 
and myeloma cells used· in the fusion is listed. The ratio of spleen 
eel-ls to myeloma cells used in all procedures was approximately 
four to one. 
The total number of wells initially screened in the MV 
ELISA immunoassay for each fusion is provided, and is directly 
correlated to the number of spleen cells used in the fusion 
procedure. The first 2 fusions were screened using goat 
anti-mouse lgG, lgA and lgM secondary antibody complex (GAM) in 
the MV ELISA immunoassay, detecting lgG, lgA and lgM producing 
clones. Subsequent screening using a goat anti-mouse lgM 
secondary antibody complex, determined that appro~imately 
90-95°/o of these were, in fact, lgM producing·. lgM producing clones 
were not as stable as lgG producing clones and may account for the 
fact that from fusions 1 and 2 we have no stable antibody 
producing cell lines, as shown in Table 5. Rather, the cell lines 
generated through these two fusions grew well, but stopped 
producing antibody after 1-2 months. Subsequent fusions, 3 and 4 , 
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Table 5: Fusion Results 
Mouse Fusion# Date 
of 
Fusion 
E2 1 4/19/90 
E3 2 4/19/90 
E4 3 7/20/90 
83 4 10/1 7/90 
Spleen Myeloma Initial 
Cells Cells Screen 
(# X 106) (# X 106) (# wells) 
246 60 2100 
145 30 1400 
330 82 2200 
136 32 1100 
Membrane 
Vessicle 
Positive 
6 6 6 * * 
3 5 2 * * 
1 8 5 * 
45* 
Working Working 
Clones Subclones 
0 0 
0 0 
3 6 
6 17 
-----------------------------------------------
--------------
** Initial screening performed using Goat Anti-mouse GAM, capable of detecting both 
lgG and lgM producing clones. 
* Initial screening performed using Goat Anti-mouse lgG, capable of detecting only 
lgG producing clones. 
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were initally screened using only goat anti- mouse lgG secondary 
antibody complex to identify lgG producing clones. This accounts 
for the decreased numbers of membrane vesicle positive wells, as 
shown in the table. 
In addition, the Friendly myeloma cell line was used for 
fusions 1 and 2. This cell line was specifically developed to be 
grown in serum..,free media, however, may not be as stable as the 
SP2/0 myeloma cell line, subsequently used in fus.ions 3 and 4, 
from which stable, antibody producing cell lines were generated. 
From fusion 3, three parent working clones were chosen by 
extensive screening procedures, and were subcloned tb yield 
monoclonal cell lines. The·se monoclonal cell lines were 
extensively rescreened and six monoclonals were chosen for 
further characterization. 
From fusion 4, six parent working clones were chosen and 
were subcloned to generate monoclonal cell lines. These 
monoclonal cell lines were extensively rescreened and seventeen 
were chosen for further characte"rization. 
C: Screening Procedures 
The nine parent working clones from fusions 3 and 4 are 
listed in Table 6. The results of each of these clones in the ELISA 
immu·noassay are expressed as the average value of multiple 
assays, and ranged from 0.11 absorbance units for clone E20C8 to 
1.55 absorbance units for clone- E18H1. HCG competitve binding 
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Table 6: Parent Clones from Fusions 3 and 4 
Table 6 provides the results of the initial screening assays for the parent working 
clones from which the selected monoclonal cell lines were derived. The data provided 
represents the average values for the multiple ELISA, hCG Inhibition, and Progesterone 
Inhibition assays performed. (*) denotes clones derived from mouse immunized for 
anti-idiotypic antibody production. 
Clone Name 
E18H1 
E20C8 
E1F8 
3 ES* 
6 F 1 1 * 
7C 1 O* 
8 E2 * 
8 H2* 
9G8* 
ELISA Results 
(absorbance) 
1 .55 
0. 1 1 
0.85 
0 .51 
0.62 
0.62 
0.33 
0. 73 
0 .41 
HCG Inhibition 
( 0/o inhibition) 
76.0 
36. 1 
23.8 
78.7 
8.1 
32.8 
44.9 
1 2 .'3 
3.0 
Prooesterone Inhibition 
( 0/o inhibition) 
18 
72 
71 
125 
1 1 1 
88 
74 
79 
97 
----------. -------
---------
---------
.----.----------
--
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assays were also performed; the results represent the average of 
multiple assays and range. from 3°/o for clone 9G8 to 78. 7°/o for 
clone 3ES. The results of each of these clones in th.e progesterone 
bioassay are expressed as the percentage of inhibition of 
progesterone secretion, and ranged from 18°/o tor clone E18H1 to 
12S0/o tor clone 3E5. 
The 65 most prom1s1ng m.onoclonal cel·I lines generated 
from these 9 parent clones is provided ·in Table 7. This represent 
approximately 10°/o of the monoclonal gene-rated, the others being 
eliminated during the screening procedures. The data provided tor 
each monoclonal cell line includes: l) the identification of the 
clone, 2) the concentration of lgG present in. the hybridoma culture 
media, values ranging from 3.9 ng/ml tor clone 9G8-2G9 to 3.0 
ug/ml for c·lone 6F11 ES, 3} the absorbance values from m-u.ltiple 
ELISA assays, including MV and purified LH/CG receptor EL_ISA 
procedures, 4) the relative ·affinity of the antibody tor the 
receptor, calculated as t_he absorbance value in the ELISA assay 
per microgra_m lgG present, values ranging from 0.43 absorbance 
units/ug lgG for clone 6F11 ES to 101.03 absorbance units/ug lgG 
for clone 9G8~ 181, 5) the percentage of inhibition from multiple 
radiolabeled hCG competitive binding assays, calculated as 
[100-(the percentage of the to"tal radio labeled hCG binding to the 
I 
receptor], 6) the relative ~potency of inhibition, calculated as the 
percentage of hCG inhibition per microgram lgG present, values 
ranging from -6100 °/o inhibition/ug lgG for clone 8E2C 1 to 5898 °/o 
inhibition/ug lgG for clone 9G8-107, 7) the progesterone content 
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Table 7: Selected Monoclonal Cell Unes Generated from the Parent Clones 
• Denotes monoclonal cell line derived from mouse immunized for anti-idiotypic antll>ody expression. 
hCG Inhibition Assays 
Clone 
# Name 
•7 3E5A9 
-
•g A12 
•11 Ell 
··12 F6 
•13 02 
•14 08 
•ts 6F11B9 
•ts D9 
•1, E5 
•22 H12 
•23 7C10B8 
-
•24 812 
·26 D9 
•27 E8 
•23 8E2Cl 
•33 8H3C3 
•34 Ell 
•35 Gl 
•36 _9G8A3 
•37 B9 
•33 C5 
•39 C7 
•41 Fl 
•49 _7Cl1B8 
•52 6F11D10 
•54 04 
•55 010 
·61 908-1 Flt 
·62 H4 
Group 
Type 
1 
3 or 1 
3 
1 
1&2 
1 
3 or 1 
3 
3 or 1 
1 or.3 
3 
1&2 
1 
5 
3or5 
2 
3 orl 
5 
1 
1 or3 
1 
1 
1 
1 or3 
1 
1 or3 
5 
2orl 
2orl 
Continued on next page -
IgG 
(ng/ml) 
14.5 
11.5 
11.5 
12.5 
10.5 
12 
25 
17 
3000 
13 
13.5 
10.5 
14 
15 
125 
12 
11 
125 
35 
11.8 
18.5 
13.5 
16.5 
11.8 
30 
15.25 
13 
20 
5 
#1 
MV 
0.553 
0.469 
0.502 
0.534 
0.432 
0.440 
1.0·34 
0.947 
0.941 
0.944 
0.704 
0.367 
0.527 
0.560 
0.105 
0.776 
0.827 
0.594 
1.055 
0.095 
0.395 
0.567 
0.955 
0.541 
0.937 
0.910 
0.933 
0.649 
0.294 
ELISA 
#2 
MV 
0.459 
0.361 
0.346 
0.196 
0.271 
0.528 
1.008 
1.064 
1.299 
0.955 
0.439 
0.122 
0.246 
0.245 
0.072 
0.530 
0.639 
0.425 
1.254 
0.056 
0.258 
0.344 
0.912 
0.284 
1.068 
0.871 
0.939 
0.850 
0.334 
#3 
MV 
0.641 
0.366 
0.414 
0.319 
0.299 
0.850 
0.937 
0.442 
0.269 
0.545 
0.151 
0.018 
0.734 
0.848 
1.092 
0.077 
0.221 
0.711 
0.763 
0.076 
0.903 
0.964 
0.721 
0.405 
#3 
LHR 
0.429 
0.150 
0.244 
0.187 
0.115 
0.460 
0.608 
0.227 
0.191 
0.478 
0.106 
0.035 
0.440 
0.585 
0.819 
0.041 
0.142 
0.402 
0.452 
0.075 
0.422 
0.591 
.0.393 
0:239 
Affinity 
Abs2'ug 
31.68 
31.43 
30.05 
15.67 
25.78 
44.04 
40.32 
6260 
0.43 
73.44 
3253 
11.66 
17.59 
16.32 
5,76 
44.16 
58.12 
33.98 
35.84 
4.76 
13.93 
25.49 
55.24 
24.04 
35.62 
57.13 
72.22 
4248 
66.82 
#1 #2 #3 
Percent Percent Percent 
Inlul> Inhll> Inhib 
9.4 -20 33.66 
10.8 25 9.49 
44.9 1.0 6.44 
48.6 20.8 5.36 
67.8 0.7 30.72 
71.9 9.5 
23.9 3.5 5.53 
18.7 -7.5 
-0.2 5.8 14.96 
320 3.8 19.05 
49.2 -6.7 
79.9 25.5 -7.25 
38.5 4.6 21.09 
69.0 4.1 21.58 
51.5 -76.3 0.00 
49.3 15.2 210 
34.3 2.0 -0.98 
46.8 6.4 
80.7 19.7 16.08 
61.7 0.0 -6.20 
59.3 12.2 7.67 
59.3 13.1 -14.36 
13.3 29.2 6.44 
81.9 1.1 16.18 
7.6 23.3 
7.4 18.1 -7.36 
19.5 8.9 -26.23 
56.5 -7.4 25.04 
56.4 .5:1 -16.99 
Blouuys 
Potency Inhll>ition Stimulation 
hCG Prog Percent Potency Prog Percent Potency 
Inhib/ug ng/ml inh.tl> Inlul>/ug ng/ml Stim Stim 
-140 768 58.0 4000 
218 700 75.0 6522 
87 652 87.0 7565 548 -67.3 -5855 
1661 744 64.0 5120 350 -133.3 -10667 
71 654 86.5 8238 884 44.7 4254 
789 820 45.0 3750 736 -4.7 -389 
142 724 69.0 2760 
-439 1032 -8.0 -471 
2 796 51.0 17 
291 740 65.0 5000 
-497 784 54.0 4000 836 28.7 2123 
2429 736 66.0 6286 952 67.3 6413 
331 760 60.0 4286 
273 932 17.0 1133 792 14.0 933 
-6100 840 40.0 3200 936 620 4960 
1270 892 27.0 2250 936 620 5167 
180 760 60.0 5455 
511 1072 -18.0 -1440 624 -420 -3360 
563 704 74.0 2114 792 14.0 400 
0 488 128.0 10847 780 10.0 847 
651 720 70.0 3784 684 -220 -1189 
968 808 48.0 3556 484· -88.7 -6568 
1767 768 58.0 3515 
94 528 118.0 10000 760 3.3 282 
778 848 38.0 1267 
1184 784 54.0 3541 
685 928 18.0 1385 
-371 744 64.0 3200 996 82.0 4100 
1142 788 53.0 10600 1092 114.0 22800 
u.) 
...r 
Table 7 Continued 
Clone 
# Name 
·63 908-2 Al 
·68 908-2 Fl 1 
·69 G3 
•70 G7 
•71 G9 
•72 H3 
•73 ,FllAS 
-
•74 F8 
•79 908-1 C5 
•82 D7 
*83 El 
•84 Fll 
*85 G2 
·88 908-1 A6 
•90 All 
•92 Bl 
•,s 812 
•% D3 
•'J7 E4 
•,s FS 
•100 F8 
•103 Ht 
•104 908-2A2· 
•10s A8 
*106 AlO 
•101 C4 
•108 C8 
•111 E7 
*113 F7 
•us G3 
•110 HS 
141 El8HlA8 
-
142 El9Ht2E5 
-
143 E20C8GS 
-
145 _ElF8 
180 P5A2Ht2 
-
Group 
Type 
2&1 
2 
5 
3 
1 
1 
1 
2&1 
1 
1&2 
3 or 2&1 
I &2 
2 
1 
2&1 
3 or 1 
2 
2 
3 
1 
J 
3 or 1 
t or3 
1 or3 
I or3 
1 
l 
3 
5 
1 or3 
1&2 
1 
2 
1 
2orl 
IgG 
(ng/ml) 
16.5 
125 
18 
24 
3.9 
13 
13.5 
16 
24 
18· 
15.5 
13.5 
8.5 
13.5 
16 
128 
22 
14.5 
17 
19 
17.5 
19 
33 
24 
13 
13 
15.9 
14.2 
11.8 
25 
11 
#1 
MV 
0.891 
0.952 
0.877 
0.719 
0.146 
0.725 
0.627 
0.703 
0.926 
0.762 
0.851 
0.692 
0.106 
0.916 
0.850 
0.910 
0.931 
0.823 
0.840 
0.153 
0.890 
0.950 
0.997 
1.145 
1.136 
1.083 
0.915 
0.836 
0.952 
1.051 
1.126 
0.830 
0.374 
0.250 
0.626 
0.085 
ELISA 
#2 
MV 
0.995 
1.109 
1.037 
0.998 
0.174 
0.834 
L021 
0.929 
1.001 
0.888 
0.998 
0.711 
0.101 
1.106 
1.344 
1.293 
1.318 
0.730 
1.351 
0.210 
0.778 
0.945 
1.130 
1.325 
1.096 
1.303 
0.778 
0.865 
1.238 
t.064 
1.266 
1.326 
0.215 
0.104 
·1.025 
0.108 
#3 
MV 
0.536 
0.8.78 
0.944 
·o.626 
1.008 
0.895 
0.857 
0.971 
0.565 
0.224 
0.023 
0.978 
0.917 
1.094 
1.058 
1.063 
1.042 
0.816 
0.966 
0.888 
1.023 
1.035 
1.004 
0.712 
0.591 
1.018 
0.915 
0.903 
0.083 
1.118 
0.008 
#3 
LHR 
0.385 
0.534 
0.578 
0.405 
0.589 
0.519 
0.389 
0.598 
0.412 
0.097 
0.015 
0.643 
0.658 
0.772 
0.638 
0.658 
0.720 
0.473 
0.656 
0.489 
0.646 
0;625 
0.436 
0.309 
0.303 
0.735 
0.533 
0.548 
0.061 
0.677 
0.034 
Affinity 
Abs2/ug 
60.31 
88.70 
57.60 
41.58 
44.68 
64.14 
75.63 
58.05 
41.70 
49.36 
64.38 
5269 
11.86 
81.92 
83.97 
101.03 
59.89 
50.35 
79.45 
40.93 
53.98 
59.49 
40.15 
45.66 
100.25 
59.82 
54.43 
87.21 
90.18 
50.63 
9.82 
hCG Inhibition A.uays 
#1 #2 #3 
Percent 
lnhib 
65.5 
19.2 
19.3 
28 
25.5 
41.7 
56.7 
50.4 
220 
78.2 
63.1 
51.7 
49.9 
27.2 
56.2 
-5.4 
74.9 
104.5 
28.0 
28.5 
9.1 
21.1 
16.8 
13.6 
14.3 
-27.4 
50.9 
-55.7 
21.9 
11.4 
79.7 
19.0 
25.5 
39.2 
23.8 
59.8 
Percent Percent 
lnhib Inlul> 
-61.7 25.64 
18.4 4.11 
9.8 
6.2 3.82 
128 13.52 
13.1 13.94 
19.7 15.83 
9.4 26.41 
11.2 30.12 
106.2 2259 
-4.8 
11.2 45.36 
-l.2 ·2263 
19.9 -1.51 
15.9 16;78 
11.6 -235 
41.3 -60.63 
21.7 58.56 
-125 -1;26 
29.2 28.23 
3.5 263 
28 20.42 
7.9 35.17 
7.8 34.92 
15.6 19.19 
220 14.54 
16.2 21.23 
-3.6 
9.1 14.85 
5.3 11.32 
13.6 21.44 
4.8 
10.8 
11.4 21.65 
-8.7 35.52 
15.4 31.77 
Potency 
ha} 
Inlul>/ug 
-3738 
1472 
543 
260 
3117 
1011 
1463 
590 
465 
5898 
-309 
2015 
-143 
1476 
994 
908 
1879 
1500 
-736 
182 
159 
414 
235 
650 
1691 
1245 
-225 
639 
450 
543 
1403 
Prog 
ng/ml 
768 
1240 
936 
740 
712 
716 
640 
732 
852 
720 
872· 
652 
1200 
712 
820 
772 
996 
900 
632 
588 
760 
652 
624· 
652 
680 
740 
560 
840 
960 
772 
488 
928 
1008 
1180 
716 
912 
Inlul>ition Stimulation 
Percent Potency Prog Percent Potency 
inlul> Inlul>/ug ng/ml Stim Stim 
58.0 3515 968 727 4404 
-60.0 -4800 
16.0 889 
65.0 1108 
720 18462 
71.0 5462 780 10.0 769 
90.0 6667 680 -23.3 -1728 
67.0 4188 964 71.3 4458 
37.0 1542 
70.0 3889 884 44.7 2481 
320 2065 872 40.7 2624 
87.0 6444 964 71.3 5284 
-50.0 -5882 872 40.7 4784 
720 5333 
45.0 2813 ·1092 114.0 7125 
57.0 4453 
1.0 45 1112 174.0 7909 
25.0 1724 .1160. 136.7 9425 
920 5412 
103.0 
60.0 3158 
87.0 4971 
94.0 4947 
87.0 2636 
80.0 3333 
65.0 5000 800 16.7 1282 
110.0 8462 636 -38.0 -2923 
40.0 2516 672 -26.0 ~1635 
10.0 704 
·s1.o 4831 
128.0 5120 872 40.7 1627 
18.0 
-20· 
-45.0 1208 1527 
71.0 
220 2000 896 48.7 4424 
1n each of the culture supernatants in the progesterone inhibition 
assay, values ranging from 488 ng/ml for clone 9G889 to 1240 
ng/ml for Clone 9G8-2F11, 8) the percentage of inhibition of 
progesterone secretion from cul tu red granulosa cells, calculated 
as [100-(the percentage of progesterone secretion from (+) hCG 
control cell cultures], (See Figure 3), values ranging from -60.0 
for clone 9G8-2F1 l to 128°/o for clones 9G8B9 and 9G8-2H5, 9) the 
potency of progesterone inhibition, calculated as the percentage of 
i n h i b it i o n per u g .I g G p res e n t , v a I u es r a n g i n g fro m -5 8 8 2 °/o 
inhibition/ u g I g G · for c Ione 9 G 8-1 G 2 to 1 8 4 6 2 °/o in h i bit ion/ u g I g G 
f o r c Io ne 9 G 8- 2 G 9, 1 O) th e pro g ester one co n ten ·t i n. each of the 
culture supernatants in the progesterone stimulation assay, val·ues 
ranging from 484 ng/ml for clone 9G8C7 to 1272 ng/ml for clone 
9 G 8- 1 B 1 2 , 1 1 ) th e p e r c e n tag e of p r o g est ero n e st i rn u I at i o n , 
calculated as [100-(the percentage of progesterone secretion from 
(-hCG) control ce-lls], (See Figure 3), values ranging from -133.3°/o 
for clone 3E5F6 to 17 4°/o for clone 9G8-1 B 12, and 12) the potency 
of stimulation, calculated as the percentage of progesterone 
stimulation per ug lgG present, values ranging from -10667 °/o 
stimulation/ ug lgG for cl·one 3 ESF6 :to 22800 °/o stimulation/ ug 
lgG, for clone 9G8-.1 H4. T·he monoclonal a·ntibodies chosen for 
tu rther characterization are h·ig hlighted in bold print. 
These monoclonal antibodies were categorized based on 
the results of the ELISA, hCG competitive binding assays an.d 
progesterone bioassays listed in Table 7. The results of this· 
categorizatiqn is provid~d in Table 8. The monoclonal antibodies 
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Table 8: Categorization of the Monoclonal Antibodies Screened 
Table 8 provides a ranking of monoclonal antibodies according to ELISA results, 
(maximum and minmum absorbance values, and highest and lowest relative affinity), 
hCG inhibition assay results, (maximum and minimum 0/o inhibition, and highest and 
lowest potency of inhibition), and progesterone bioassay results, (maximum 
progesterone inhibition , highest potency of inhibition, maximum 0/o stimulation, and 
highest potency of stimulation). 
MAXIMUM ABSORBANCE 
Clone Number 
9G8-1 E4 97 1 .351 
9G8-1A1 90 1 .344 
E18H1A8 141 1 .326 
9G8-2A8 105 1.325 
9G8-181 95 1 .31 8 
9G8-2C4 107 1.303 
6F11E5 19 1.2.99 
9G8-181 92 1.293 
9G8-2H5 120 ; .266 
9G8A3 36 1.254 
9G8-2F7 113 1.238 
9G8-2A2 104 1 .130 
9G8-2F1 68 1. 109 
9G8-1 A6 88 1.106 
9G8-2A 1 106 1.096 
6F11D10 52. 1.068 
9G8-2G3 115 1 .064 
6F11D9 18 1.064 
9G8-2G3 69 1.037 
E1F8 145 1.025 
6F11A5 73 1 .021 
HIGHEST RELATIVE AFFINITY 
Clone Number 
9G8-181 92 
9G8-2C4 107 
9G8-2G3 115 
9G8-2 F 1-1_ 68 
Abs/ug 
1 01 . 03 
100.25 
90.18 
88.70 
ELISA RESULTS 
36 
MINIMUM ABSORBANCE 
Clone Number 8bs 
9G889 37 0.056 
8E2CC1 28 0.072 
9G8-1 G2 85 0.101 
QE20C8G5 143 0.104 
P5A2H12 180 0. 108 
7C10812 24 0.122 
9G8-2G9 71 0.174 
3E5F6 12 0.196 
9G8-1 FS 98 0 .. 210 
E19H12E5 142 0.215 
7C10E8 27 0.245 
7C10D9 26 0.246 
9G8C5 38 0.258 
3E5G2 13 0.271 
7C-1188 49 0.284 
9G8-1 H4 62 0.334 
9G8C7 39 0.344 
3E5E11 11 0.346 
3E5A12 8 .0.361 
8H3G1 35. 0;425 
7c·1088 23 0.439 
LOWEST RELATIVE AFFINITY 
Clone Number 
6F11E5 19 
9G889 37 
8E2C1 28 
P5A2H12 180 
Abs/ug 
0.43 
4.76 
5.76 
9.82 
(Table 8 continued) 
9G8-2F7 113 
9G8-1 A 11 90 
9G8-1 A6 88 
9G8-1E4 97 
6F11 A5 73 
6F 11 H 12 22 
6F11G10 55 
9G8-1 H4 62 
9G8-1 E 1 83 
9G8-2H3 72 
6F1109 18 
9G8-2A 1 63 
9G8-1 B 1 95 
9G8-1 C8C8 1 08 
87.21 
83.97 
81.92 
79.45 
75.63 
73.22 
72.22 
66.82 
64.38 
64.14 
62.60 
60.31 
59.89 
59.82 
7C10812 
9G8-1 G2 
9G8C5 
3E5F6 
7C10E8 
7C1009 
7C 1188 
9G8C7 
3E5G2 
3E5E11 
3E5A12 
3E5A9 
24 
85 
38 
12 
27 
26 
49 
39 
13 
1 1 
8 
7 
11. 66 
11 . 86 
13. 93 
15 .67 
16 .32 
17 .59 
24.04 
25.49 
25. 78 
30.05 
31 .43 
31 .68 
-----------------------------------------------
--------------
HCG INHIBITION RESULTS 
-----------------------------------------------
--------------
MAXIMUM 0/o INHIBITION MINIMUM 0/o INHIBITION 
Clone Number 0/o Inhibition Clone Number 0/o Inhibition 
9G8-1 03 96 81 .5 9G8-2E7 1 1 1 0.0 
9G8-1 07 82 69.0 9G8-181 92 3.9 
7C10812 24 52.7 9G8-2G7 70 4.3 
9G8-2H5 120 50.6 9G8-1 F8 100 5.1 
3E5G2 13 49.2 6F11E5 19 6.9 
7C1188 49 49.0 6F11 G4 54 8.5 
9G8-1 F1 84 48.5 9G8-t E4 97 9·.3 
P5A2H12 180 45.8 6F1109 18 9.3 
9G8-2A 1 63 45.6 6F11G10 55 9.5 
7C10E8 27 45.3 3E5A12 8 1 0 .1 
9G8-1 F1 61 4·0.8 -6F1189 15. 11 . 0 
3E5G8 14 40. 7 E18H1-A8 141 11 . 9 
9G8A3 36 ·38.8 8H3E11 34 1 2. 1 
9G8-1B1 95 3.8. 7 9G8-2C4 107 12·.2 
6F11 Fa· 74 38.4 9G8-2F1 68 14 ;0 
HIGHEST RELATIVE POTENCY OF INHIBITION LOWEST RELATIVE POTENCY OF INHIBITION 
Clone 
9G8-107 
Number 
82 
% lnhibition/ug lgG Clone 
5897 .98 8E2C1 
37 
Number % lnhibition/ug lgG 
28 -6100.36 
(Table 8 continued) 
----------------------------------------------- -~-- - ~-- -- -- ~- --
9G8-2G9 71 3277 .39 9G8-2A 1 63 -3737.74 
7C10B12 24 2429.44 9G8-1 E4 97 -735.83 
9G8-1 F1 84 2014.81 7C10B8 23 -496.97 
9G8-181 95 1878.51 6F11 D9 18 -438.50 
9G8F1 41 1767.49 9G8-1 F1 61 -370.91 
9G8-2C4 107 1690.91 9G8-1E1 83 -308.50 
3E5F6 12 1661.09 9G8-2E7 1 1 1 -225.27 
9G8-1 D3 96 1499.69 9G8-1 G2 85 -143.32 
9G8-1 A6 88 1476.09 3ESA9 7 -140.44 
9G8-2F1 68 1472.00 9G8B9 37 0.00 
6F11AS 73 1462.63 6F11ES 19 1.94 
P5A2H12 180 1403.31 3ESG2 13 71.00 
8H3C3 33 1269.70 3E5E11 1 1 86.96 
9G8-2C8 108 1244.76 7C 1188 49 93.99 
----------. ------------------------------------.--------------
PROGESTERONE INHIBITION RESULTS 
-------------------------------------------------------------
MAXIMUM 0/0 INHIBITION 
Clone Number o;o lohibiiton 
9G8-2H5 120 128.0 
9G889 37 128 .. 0 
7C11B8 49 118 .0 
9G8-2C8 108 110 .0 
9G-8-1 FS 98 103.0 
9G8-2A2 104 94.0· 
9G8-1 E4 97 92.0 
6F11 AS 73 90.0 
9G8-2A8 105 87.0 
3ESE11 1 1 87.0 
9G8-1 H 1 103 87.0 
9G8-1 F1 84 87.0 
3ESG2 13 86.5 
9G8-1A1 106 80.0 
3ESA12 8 75.0-
HIGHEST RELATIVE POTENCY OF INHIBITION 
Clone Number 
9G8-2G9 71 
9G8B9 37 
9G8-1 H4 62 
0/o lnhibition/ug lgG 
18462 
10847 
10600 
38 
(Table 8 continued) 
.------------------------- ------- . -- ----------------------
7C 1188 49 
9G8-2C8 108 
3E5G2 13 
3E5E11 11 
6F11A5 73 
3E5A12 8 
9G8-1 F1 84 
7C10812 24 
9G8-2H3 72 
8H3E11 34 
9G8-1 E4 97 
9G8-1 A6 88 
9G8-2H5 120 
3E5F6 12 
9G8-2C4 107 
10000 
8462 
8238 
7565 
6667 
6522 
6444 
6286 
5462 
5455 
5412 
5333 
5120 
5120 
5000 
_______________________________________________ , __________ , ___ _ 
PBOOESTERONE STIMULATION RESULTS 
---------------------------------------------,------------·-----
MAXIMUM STIMULATION 
Clone Number 
9G8-1 B 1 95 
E20C8G5 143 
9G8-103 96 
9G8-1 H4 62 
9G8-1A1 90 
9G8-1 F1 61 
9G8-2A 1 63 
9G8-1 F1 84 
6F11F8 74 
7C10812 24 
0/0 Stimulation 
174.0 
152.7 
136.7 
114. 0 
114 .0 
82.0 
72.7 
71.3 
71.3 
67.3 
HIGHEST RELATIVE POTENCY OF STIMULATION 
Clone Number 
9G8-1 H4 62 
9G8-103 96 
9G8-181 95 
9G8-1 A 1 90 
7C10812 24 
9G8-1F1 84 
010 Stim/ug laG 
22800 
9425 
7909 
7125 
6413 
5284 
39 
(Table 8 continued) 
-·------. ---- .--------------------------------------·--· ._. ----· 
8H3C3 
8E3C1 
9G8-1 G2 
33 
28 
85 
5167 
4960 
4784 
------------------------------------------------------------- - -
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were ranked according to average absorbance values in the ELISA 
immunoassay, and a listing of those with maximum and minimum 
.absorbance is shown, values ranging from 0.056 absorbance units 
·for clone 9G8B9 to 1.351 absorbance units for clone 9G8-1 E4. The 
.relative affinity of each antibody was also ranked and a listing of 
those with highest and lowest relative affinity is provided. The 
values ranged from 0.43 absorbance units/ug lgG for clone 6F11 ES 
to 101 .03 absorbance units/ug lgG for clone 9G·8-1 B 1. From the 
results o-f multiple hCG competitive binding assays, antibodies 
demonstrating .the highest and lowest average percentage of 
inhibition are listed. These values range from 0°/o for clone 
9G8-2E7 to 81 .So/o for clone 9G8-103. The potency of inhibition for 
each antibody was also ranked and a listing of the antibodies with 
highest and lowest potency is also provided, values ranging from 
-61 0 0 . 3 6 °/o in hi bit on/ u g · I g G for c Ione 8 E 2 C 1 to 5 8 9 7. 9 8 °/o 
in h i bi.ti o n / u g I g G f o r c Io n e 9 G 8-1 D 7. The res u Its o·f the 
progesterone bioassay were also categorized. Antibodies showing 
the highest percentage of progesterone. inhibition are listed, clone 
9G8-2H5 demonstrated the highest degree of inhibiton with a 
value of 128°/o. Clone 9G8-2G9 demonstrated the greatest potency 
of progesterone inhibiton with a value of 18462 °/o inhibition/ug 
lgG. In addition, monoclonal antibodies de·monstrating the highest 
percentage of progesterone sti·mulation are listed, clone 9G8-1 B1 
demonstraing the highest value with 174°/o stimulation, as well as 
those demon$trating th~ highest potency of progesterone 
stimulation, clone 9G8-1 H4 being the highest with a value of 
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22800 o/o stimulation/ug lgG. 
This categorization data was used in the screening and 
selection process. The monoclonal antibodies which demonstrated 
the best resu.lts in each of the categories described in Tabl.e 8 
were subcloned .by limiting dilution i'n order to validate that they 
were indeed monoclonal in origin and to select those cells from 
each clone which were the best antibody s.ecretors. In addition to 
the data generated on each monoclonal cell line, the growth of the 
clones in cell culture also greatly influenced the final selection 
process, (i.e. some of the cell· lines grew well in culture, however 
stopped producing antibodies after multiple cell divisions, other 
cell lines were unstable in cell culture and eventually died out). 
Based on the results of the screening assays developed 
duri.ng this research, ( i.e ELISA, hCG competitive binding assay 
and bioassays for progesterone inhibition and stimulation), 
anti-LH/CG receptor antibodies can be classified into 1 of 6 
theoretical categories. The 6 theoretical classifications are 
proposed in ·Table 9. Antibodies included in Group 1 would 
demostrate. binqing to the receptor in the ELISA immunoassay, 
inhibit radiolabeled hCG binding to membrane vesicles and inhibit 
progesterone secretion from cultured gran.ulosa cells. Antibodies 
categorized as belonging to Group· 2 would demonstrate binding to 
the receptor in the ELISA immunoassay, would inhibit radiolabeled 
hCG binding to membrane vesicles, and would stimulate 
progesterone secretion from cultured granulosa cells. Antibodies 
categorized as belonging to Group 3 would demonstrate binding to 
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Table 9: The 6 Theoretical Classifications of Anti-LH/CG Receptor 
Antibodies. 
ELISA: ( +) indicates binding activity to the LH/CG receptor; *hCG Biodioo: (-) 
indicates a decrease in radiolabeled hCG to membrane vessicles versus control values; 
( +) indicates that radiolabeled hCG can still bind to membrane vesicles when compared 
to control values; Progesterone Secretion: (-) indicates that progesterone secretion is 
lower than that of control cells, (i.e. granulosa cells with hCG alone, no antibody); ( +) 
indicates that progesterone secretion is higher than that of control cells, (i.e. granulosa 
cells with no hCG, only antibody); (0) indicates that no effect is seen. 
Group# 
1 
2 
3 
4 
5 
6 
ELISA Results 
+ 
+ 
+ 
+ 
+ 
+ 
*hCG Binding Results 
+ 
+ 
+ 
43 
Progesterone Secretion 
+ 
+ 
0 
0 
the receptor in the ELISA immunoasay, would not inhibit hCG. 
binding to membrane vesicles but would inhibit progesterone 
se.cretion from cultured granulosa cells. Antibodies designated as 
belonging to Group 4 would demonstrate binding to the receptor on 
ELISA immunoassays, would not inhibit hCG binding to membrane 
vesicles and would stimulate progesterone secretion from 
cultured granulosa cells. Antibodies of Group 5 would demonstrate 
binding to the receptor 1n the ELISA immunoassay, would not 
inhibit hCG binding to membrane vesicles and would show no 
effect on progesterone secretion versus control values. 
Antibodies of Group 6 would demonstrate binding to the receptor 
on the ELISA immunoassay, would inhibit hCG binding to membrane· 
vesicles and would show no effect on progesterone secretion 
versus control values. 
Based on this classification, the monoclonal antibodies 
chosen for further characterization were categorized. The results 
are provided in Table 10. Clone #s: 11 and 97 demonstrated the 
ability to bind to the receptor in the ELISA immunoassay, did not 
block the binding of radiolabeled hCG to the receptor but display·ed 
the ability to inhibit progesterone secretion from granulosa cells 
in the presence of hCG. These clones were classified ·as group 3. 
Clone #s: 36,73, 98, 108, 141 and 145 all demonstrated the ability 
to bind to the receptor in the ELISA immunoassay, the ability to 
block radiolabeled hCG binding to the receptor, and also the ability 
to inhibit progesterone secretion from granulosa cells in the 
presence of h.CG and were classified as group 1. Clones#s: 95 ,96, 
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Table 1 O; Classification of the Selected Monoclonal Antibodies 
Table 1 O provides the listing of each monoclonal antibody and its categorization into 1 of 
the 6 theoretical groups, based on results of the screening assays. The designation'3 or 
1' indicates that progesterone secretion is inhibited, however, the results of the 
radiolabeled hCG competitive binding assay provides inconclusive results, primarily 
demonstrating no degree of hCG inhibition. The designation · 1 & 2' indicates that hCG is 
inhibited from binding to the receptor in the hCG binding assay, and the results of the 
progesterone indicate that when antibody plus hCG is added to cultured granulosa cells, 
progesterone secretion is inhibited, however when antibody alone is added to the 
granulosa cells, progesterone secretion is stimulated. The designation '6 or 5' indicates 
that no effect on progesterone secretion is seen in the bioassay, however inconclusive 
results were obtained from the hCG competitive binding assay, primarily indicating 
that hCG binding was inhibited. The designation '1 or 3' indicates that progesterone 
secretion is inhibited in the progesterone bioassay, however, the results of the hCG 
binding assay were inconclusive, primarily indicating that hCG is inhibited from 
binding to the receptor. (*) denotes clones derived from mouse immunized for 
anti-idiotypic antibody production. 
Clone Clone Number Theoretical Group 
E35E11* 1 1 3 
6F11 ES* 19 3 or 1 
7C10812* 24 1 &.2 
8H3G1* 35 6 or 5 
9G8A3* 36 1 
7C1188* 49 1 or 3 
6F11A5* 73 1 
9G8-1 D.7* 82 1 &2 
9G8-1F12* 84 1 &2 
9G8-181* 92 3 or 1 
9G8-1812* 95 2 
9G8-1-D3* 96. 2 
9G8-1 E4* 97 3 
9G8-1F5* 98 1 
9G8-2C8* 1-08 1 
9G8-2F7~ 1 1 3 6 or 5 
9G8-2H5* 120 1 & 2 
E18H1A8 1 4 1 1 
E20C8G5 143 2 
E20C8H9 144 2 
E1F8 145 1 
. .. - --
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143 and 144 demonstrated the ability to bind to the receptor in 
the ELISA immunoasay, the ability to block radiolabeled hCG 
binding to the receptor, and also the ability to stimulate 
progesterone secretion from granuldsa cells in the absence of hCG 
and were classified as group 2. Clones #s: 19 and 92 demonstrated 
the ability to bind to the receptor in the ELISA immunoassay, the 
ability to inhibit progesterone secretion from granulosa cells in 
the presence of hCG, how.ever the results of the radiolabeled hCG 
competitive binding assay are inconclusive, primarily 
demonstrating no dAgree of hCG inhibition , hence were classified 
as group 3 or 1. Clones _#s: 24, 82, 84, and 120 demonstrate the 
ability to bind to the receptor in the ELISA imunoassay, the ability 
to block radiolabeled hCG binding to the receptor, however the 
results of the progesterone bioassay are inconclusive. In the 
presence of hCG these antibodies demonstrate an inhibitory effect, 
however in the absence of hC.G these antibodies demonstrate the 
ability to stimulate progesterone secretion hence were classified 
as groups 1 &2. Clone #s: 35 and 113 demonstrated the ability to 
bind to the receptor in the ELISA immunoassay, showed no effect 
on progesterone secretion, however, the resu Its of the 
radiolabeled competitive binding assay were inconclusive, 
primarily demonstrating an inhibitory effect and were classified 
as group 6 or 5. Clone# 49 demonstrated the ability to bind to the 
receptor 1n the ELISA immunoassay, the ability to inhibit. 
progesterone secretion from granulosa cells in the presenc~ of 
hCG, however the results of the. hCG competitive binding assay 
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were inconclusive, primarily demonstating no ·inhibition of 
radiolabeled hCG bi.nding and was classified as. group 3 or 1. 
Representatives of each of the respective groups, except 
Group 4., is included in o.ur selection of monoclonal antibodies for 
fµrther study. Interestingly, no antibodies representative of Group 
4 were detected. 
D: Characterization 
The results of the antibody typing assay are provided in 
Table 11. Al.I of the monoclonal antibodies are of the lgG2 b 
subclass, with the exception of clones #s: 97 and 113 which .are of 
the lgG1 subclass. 
Figure 1 depicts porcine granulosa cells in culture. Human 
granulosa cells in culture are shown in Fig·ure 2. These cells have 
been grown in culture for 7 days in the presence of follicle 
stimulating hormone (FSH) in order to induc~ the process of 
luteinization, thus maximizing the number of LH/CG receptors 
present on the cell surface·. 
The results of the cellular ELISA immunoassays, hCG 
binding competition assays, and progest~rone bioassays on both 
porcine and human granulosa cells are summarized in Table12. 
For each of the cellular ELISA ·immunoassys performed, the 
absorbance value for each monoclonal antibody was expressed as a 
percentage of the maximum absorbance fo.r that particula.r assay. 
The average 0/o maximum absorbance vaiue of each monoclonal 
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Table 11; lgG Subclass of Selected Monoclonal Cell Lines 
(*) denotes monoclonal cell lines derived from mouse immunized for anti-idiotypic 
antibody production. 
Clone Clone Number loG Subclass 
·--·-·--~-- ·- -
,- ----- -- - -- -- ·--
E35E11* 1 1 lgG2b 
6F11 ES* 19 lgG2b 
7C10812* 24 lgG2b 
8H3G1 * 35 lgG2b 
9G8A3* 36 lgG2b 
7C11B8* 49 lgG2b 
6F11A5* 73 lgG2b 
9G8-107* 82 lgG2b 
9 G 8·-1 F 1 2 * 84 lgG2b 
9G8-181* 92 lgG2b 
9G8-1B12* 95 lgG2b 
9G8-103* 96 lgG2b 
9G8-1 E4* 97 lgG1 
9G8-1 F5* 98 lgG2b 
9G8-2C8* 1 0 8 lgG2b 
9G8-2F7* 1 1 3 lgG1 
9G8-2H5* 1 2 0 lgG2b 
E18H1A8 1 4 1 lgG2b 
E20C8G5 143 lgG2b 
E20C8H9 144 lgG2b 
E1F8 145 lgG2b 
E1F8A3 145a lgG2b 
, 
E1F8811 145b lgG2b 
E1F8G7 145c lgG2b 
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Figure 1: Porcine Granulosa Cells in Culture. Cells were 
grown for 7 days in the presence of FSH to induce 
luteinization. The approximate magnification is 150X. 
Figure 2: Human Granulosa Cells in Culture. These cells have 
been grown for 7 days in the presence of FSH to induce 
luteinization. The approximate magnification is 150X. 
"fq 
Table 12: Results of Assays on Porcine and Human Granulosa Cells 
• Denotes monoclonal cell line derived from mouse immunized for anti-idiotypic antibody expression. 
C.t.A.v ELISA c... hCG lnhllillon ~Ollt BiouMy 
Clo,,. lgG Cone Avg% MaxAba Potency Avg% lnhl>. Pot,ency Avg% lnhb. Pot.ncy Avg% S1in Pot,ency 
(mwmt) Pig H\.fTlan Pig Hl.fflal'l Pig Hl.fflal'l Pig H\.nW'I Pig H1.rn1n Pig H1.rn1n Pig Hunan Pig HlnW'I 
*19 1.2 14.2 53.0 11.8 44.2 38.6 49.7 321 41.4 61.3 12.2 42.8 10.2 "9.1 8.7 40.9 6.8 
~ 26 10.4 33.0 4.2 13.2 4.6 48.9 1.8 19.8 8.1 Z7.2 3.2 10.9 n4 28.8 29.0 10.7 
*36 10.0 13.4 25.0 1.3 25 38.8 11.1 3.7 1.1 0.0 0.0 0.0 0.0 11.0 4.9 1.1 0.6 
*36 3.1 9.5 24.0 3. 1 7.7 34.8 88.7 11.2 22.2 26.4 18.1 8.6 6.8 68.7 32.6 18.9 10.6 
*49 20 10.5 29.0 5.3 14.5 78.6 26.0 38.3 13.0 80.0 18.1 30,0 8.1 22.4 18.7 11.2 9.4 
*73 0.0 5.0 27.0 688.0 3178.4 17.6 13.2 2068.8 1562.9 21.8 9.9 25&4.7 1184.7 33.8 no 3978.4 8470.S 
*82 1.9 13.0 14.0 8.8 7.4 22.9 25.2 120 13.3 73.3 15.9 38.8 8.4 12.4 18.8 8.6 9.8 
*84 0.4 7.5 34.0 20.3 91.9 8.4 18.9 22.7 46.8 25.8 o:o 118.2 0.0 10.4 .37.7 28. 1 101.9 
*92 1.8 18.7 33.0 9.3 18.3 30.0 19.3 18.8 10.7 7.9 95.0 4.4 62.0 2(>:4 7.4 11.3 4.1 
"96 9.7 37.0 24.8 7U 23 18.2 22.4 31.9 
<Tl '"96 8.0 9.3 47.0 1.6 ·7.8 32.8 9.7 6.4. 1.6 19.6 26 3.3 0.4 127 0.0 2.2 0.0 
0 
*97 0.4 12.3 84.0 36.0 183.0 60.8 44.1 146.0 125.9 46.3 20.1 129.4 67.4 13.8 9.3 39.4 26.8 
*98 1.0 28.4 38.0 26.9 38.8 32.7 38.3 33.3 40.2 0.0 ZT.O 0.0 ZT.8 3.4 46.8 3.6 47.6 
*108 9.5 100.0 100.0 10.5 10.6 32.7 33.2 3.4 3.5 15.9 14.2 1.7 1.2 20.4 6.4 2. 1 0.8 
*113 1.5 12.7 43.0 8.4 28.7 8.0 61.3 4.0 34.2 38.8 2.5 26.6 1.6 24.4 104.4 18.3 89.8 
*120 4.3 9.4 30.0 2.2 7.1 33.8 41.7 8.0 9.8 21.5 0 .. 0 6.1 0.0 22.4 6.4 6.3 1.3 
141 "9.5 9.0 37.0 1.0 3.9 n2 20.6 7.8 2.2 106.4 0.0 11.1 0.0 3.4 8.9 0.4 0.7 
143 5.5 <1.1 24.0 <.2 4.4 28.8 20.8 5.2 3.8 37.6 9.3 8.8 1.7 18.7 0.0 3.4 0.0 
144 8.0 11.9 46.0 1.5 5.8 65.8 61.6 7.0 6.5 26.4 0.0 3.3 0.0 8.4 6.7 18.4 0.8 
E1F8A3 1.2 22.0 28.0 18.3 23.3 0.0 64.4 0.0 53.7 0.0 74.1 0.0 61.8 30.1 5.0 25.1 4.2 
E1F8811 1.2 22.0 21.0 18.3 17.6 18.9 53.2 14.0 44.3 20.6 89.3 17.0 67.8 46.4 4.6 38.7 3.8 
E1F8G7 1.4 32.7 37.0 23.4 4.2 ·1.4 49.6 1.0 36.4 53.3 19.8 38.1 10.1 12.4 8.7 8.9 4.8 
E18 2.4 18.3 10.0 7.6 4.2 89.3 89.2 37.2 37.2 22.4 0.0 9.3 0.0 
antibody ind i Gates the average v a I u e of m u It i p I e assays. The 
results of the cellular ELISA were expressed in this ·manner in 
order to eliminate interassay variability. The potency was 
calcul.ated as the average maximum absorbance value per· lgG 
concentration, mg/ml. 
The resu Its. of the eel lular ELI SA immunoassay indicate 
that each of the monQclonal antibodies bound to the porcine as 
well as the human granulosa cells in culture. Consistently, 
monoclonal antibody 9G8-2C8., (#108) demonstrated maximum 
absorbance values for both porcine and human cells in all assays 
performed. Interestingly, most of the monoclonal antibodies 
exhibited greater absorbance readings with the h urn an cells as 
opposed to the porcine cells, approximately four times greater. 
Clones 9G8-1 D7 ( #82), E 1 F8A3 (#145a), E 1F8811 (#145b), and 
E 1 F8G7 (145c), however demonstrated approximately the same 
degree of absorbance for both. porcine and human granulosa cells. 
In the ce.llular hCG co.mpetitive binding assay$·, the. 
average 0/o i n h i bit ion i n d i cat es the average v a I u e of mu It i p I e 
inhibition assays performed on both porcine and human cells, 
respectively. The potency was c.alculated as the average 0/o 
inhibition per lgG concentration, mg/ml. 
The results of the cellular hCG competitive. binding assays 
indicate ·that all of the monoclonal antibodies were capable of 
blocking radiolabeled hCG binding to porcine as well as human 
cells, although a broad range of potency was seen. Furthermore, 
each monoclonal antibody did not demonstrate the same degree of 
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inhibition in porcine versus human cells. Some of the antibodies, 
such as 8H3G1 ('#35), 7C1188 {#49), and 9G8-103 (#96) produced 
·a significantly greater de.g ree of inhibition in porcine ce 1·1s, 
(36.8°/o, 78.6°/o and 32.6°/o, respectively) as opposed to human cells, 
( 1 1 . 3 °/o, 2 6 °/o and 9 . 7 °/o , respect i Ve I y) . 0th er anti b O d i es' s u Ch as 
9 G 8-2 F 7 ( # 1 1 3) , 9 G 8 A 3 ( # 3 6) , and 9 G 8- B l 2 ( # 9 5) prod u c e d a 
s i g n if i cant ly g re ate r deg re e of i n h i bit i o n i n h u man c e 11 s , (5 1 . 3 °/o , 
68. 7°/o and 71.4°/o, respectively) as opposed to porcine cells, ( 6°/o, 
34.8°/o and 24.6°/o, respectively). For some antibodies, such as 
E20C8H9 (#144), 9G8-107 (#82), and 9G8-2C8 (#108) the degree 
of inhibition was nearly indentical in both porcine and human 
ce 11 s, ( 5 5. 6 °/o, 2 2. 8 5 °/o and 3 2. 7 °/o Vs. 5 1 . 6 °/o, 3 5. 2°/o and 3 3 . 2 °/o' 
respectively). 
In the progesterone bioassays, the average 0/o inhibition and 
the average 0/o stimulation, were calculated as the average of 
multiple assays performed on both porcine. and human cells. The 
potency was determined by calculating the percent progesterone 
inhibition per lgG concentration, mg/ml and percent progesterone 
stimulation per lgG concentration, mg/ml, respectively. 
The results of the progesterone bioassays demonstrate the· 
s·ame phenomenon displayed in the radiolabeled hCG competitive 
binding assay; all of the monoclonal antibodies exhibited some 
deg re e of bi op o ten c y to i n h i bit or st i m u I ate pro g ester one 
secretion from granulosa cells in culture, however, the effects of 
each specific antibody were not identical when comparing porcine 
and human cells. Two examples are highlighted: clone E35E11 
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(#11) demonstrated a 105.4°/o inhibition of progesterone secretion 
from porcine granulosa cells in the presence of hCG, but a 0°/o 
inhibition of progesterone secretion from human granulosa cells. 
Clone 9G8-181 (#92.), however, demonstrated a 95°/o inhibition of 
progesterone secretion "from human granulosa cells, but only a 
7.9°/o inhibition of progesterone from porcine granulosa cells. 
Fi.gure 3 represe.nts a graphical depiction of fhe data 
shown in Tab.le 12, summarizing the results of the cellular assays 
performed on both porcine and human granulosa cells. 
The effect of a monoclonal antibody to either inhibit or 
stimulate progesterone secretion from granulosa cells in culture, 
in theory should be mutually exclusive, (i.e. antibodies which show 
an inhibitory effect on progesterone secretion should show· little 
or no abi.lity to stimulate progesterone secretion, and vice versa). 
Most likely antibodies which are most specific for the activation 
site of the receptor, (i.e. capable of mimicking the ligand and 
resulting in an activation of the cell), will de.monstrate a 
simulatory effect on progesterone secre.tion. Conversely, 
antibodies specific for an epitope within or near the binding site, 
but not necessarily the receptor activation site, most likely will 
inhibit ligand binding, (i.e. hCG binding), and result in an overall 
inhibitory effect on progesterone secretion. 
Two specific examples highlight this phenomenon and they 
are discussed in more detail. Clone 9G8-2F7 (#113), exhibited a 
sig.nificantly higher degree of progesterone inhibition, 
approximately 16-fold greater, in porcine cells versus human 
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Figure 3: Graphical depiction of the data shown in Table 12: 
Cellular ELISA immunoassays (panel A), hCG competitive binding 
assays (panel B), and progesterone bioassays (panels C and D). 
Assays performed on cultured granulosa follicular cells (white 
bars - human cells, black bars - porcine cells). Control bar 
panel B (excess hCG) - 100% inhibition of 125!-hCG binding. 
Control bar panel c (+hCG) - 100% stimulation of progesterone 
secretion. 
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ce 11 s , ( 3 9 . 8 °/o vs , 2 . 5 °/o, respective I y) . Howe v e r, i n the pro g est e r o n e 
stimulation -assay, this antibody demonstrated a significantly 
higher degree of stimulation, approximately 4-fold greater, in 
h u m a n as O pp Os e d t O p O r Ci n e Ce 11 s I ( 1 0 4 . 4 °/o Vs. 2 4 . 4 °/o' 
respectively). Interestingly, these results indicate that this 
specific monoclonal an ti.body differentially interacts with porcine 
as opposed to human cells, prod u.ci ng an inhibitory effect on 
progesterone secretion from porcine cells but a stimulatory effect 
on human .cells. 
The results of clone 7C1OB12 (#24) also indicate a 
differential interaction with porcine as opposed to human cells. In 
the progesterone inhibition a.s.say, a 3-fold great.er degree of 
inhibition was seen in human cells as opposed to porcine cells 
( 2 7 . 2 °/o vs . 8 . 1 °/o , respective I y) ; h owe v e r i n th e pro g est e r o n e 
stimulation assay, a 3-fold greater degree of stimulation was 
seen in porcine as opposed to human cells, ( 72.4°/o vs. 26.6°/o, 
respectively). Thus, these results indicate the converse of clone 
9G8-2F7, producing an inhibitory effect on progesterone secretion 
from human cells, but a stimulatory effect on progesterone 
secretion from porcine cells. 
Figures 4 and 5 display the diffuse fluorescence pattern 
produced after administration of rhodamine labeled secondary 
anti.body to the surface of porcine and ·human cells, respectively, 
at time 0, (i.e. immediately following assay procedure). Following 
a 3 hour incubation at 37'C, however, the formation of small 
fluorescent. patches or aggregates was seen, (see Figure· 6) 
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Figure 4: Fluorescent microscopy. Porcine granulosa cell in 
culture stained with monoclonal antibody #108 and TRITC goat 
anti-mouse IgG, at time o. 
Figure 5: Fluorescent microscopy. Human granulosa cell in 
culture stained with monoclonal antibody #108 and TRITC goat 
anti-mouse IgG, at time o. 
5lo 
' .~ i .· . ., 
Figure 6: Fluorescent microscopy. Human granulosa cells in 
culture stained with monoclonal antibody 145c and TRITC goat 
anti-mouse IgG. a) at time o; b) at time 3 hours. 
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presumed to be receptor/antibody complexes on the surface of the 
cells or possibly internalized within the cells. 
The resu Its of the Western transfer/i mm_u noblotting 
procedure are represented in Figure 7 which depicts those 
antibodies .which displayed significant binding to the porcine 
receptor band in the immunoblot procedure using the IBI Enzymatic 
Web (Kodak I n c.) , c Ione s # s : 1 4 1 , 1 9 , 1 0 8 , 1 1 , 4 9 , 2 4 , and 3 6 , 
respectively; Unfortunatel_y, this includes only approximately 30°/o 
of the monoclonals selected for characterization stud i-es. 
In addition to por9ine ovarian membrane extracts used for 
the Western transfer/ immunoblotting procedures, porcine liver 
and spleen extracts were also prepared and run in parallel with 
these procedures. The immunoblots on both liver and spleen ti'ssue 
extracts were consistently negative for all monoclonal antibodies 
used. 
The results of the Western fransfer/immunoblotting 
procedures on the human ovarian membrane protein, run in parallel 
with the porc1 ne Western transfe.r/i·m mu noblotti ng procedures, 
were all negative. This may be related to the !ability of the 
receptor and a loss of receptor binding capacity as a result of 
tis.sue storage at -70'C prior to ho mag en ization/so I u bi I izatio.n 
procedures and freezing/thawing of the ovarian membrane extac.t 
prior to use. 
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Figure 7: Western Transfer /Immunoblotting to the Porcine LH/CG 
Receptor. Monoclonal antibody samples: a) lane 1, #141; lane 
3, #19; lane 5, #35; lane 7, #82; lane 9, #92; lane 11, # 98; 
lanes 2, 4, 6, 8, 10 &12, controls. b) lane 1, #108; lane 3, 
#11; lane 5, # 49; lane 7, #24; lane 9, #36; lane 11, #84; 
lanes 2, 4, 6, 8, 10, 12 and 13, controls. Migration of 
molecular weight markers are shown on the left: Myosin 205K, 
B-galactosidase 116K, Phosphorylase b 97.4K, Albumin (Bovine) 
66K. Estimated MW of the presumed LH receptor, 73.5K. This is 
in agreement with values reJijorted in the literature. 
Although a few reports 1n the literature describe 
antibodies to the mammalian LH/CG receptor, 16,17,18,19,20 ,21
 these 
antibodies have been almost exclusively polyclonal in nature, 
produced primarily to the rat LH/CG receptor, and have been used 
predominantly for receptor localization studies using 
immunohistochemical techniques. The further eluci.dation of the 
structure/function of th is receptor, in particular the mechanism of 
receptor activation, would be facilitated by the production of 
monoclonal antibodies specific for the ligand binding site of this 
receptor. Monoclonal antibodies would be superior to conventional 
polyclonal antisera for several reasons, 22 including: 1) monoGlonal 
antibodies are directed against a single epitope (antigenic 
determinant) on a molecule, whereas conventional· antisera contain 
a population of antibodies against several epitopes on a molecule; 
2) monoclonal antibodies are homogeneous with respe.et to affinity 
and specificity. (Conventional antisera contain antibodies which 
vary greatly in affinity); 3) virtually an unlimited supply of 
well-defined antibody is available because hybridomas can be 
frozen and when recovered at a later date, will continue to produce 
the same monoclonal antibodies. (Due -to the dynamic nature of the 
~ 
immune response, no conventional antisera is exactly like another. 
This is true even from bleeds from the same animal); 4) monoclonal 
antitJoqies can be "tailor made", with regard to affinity, subclass 
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restriction, binding activity, .etc., by selecting the proper assays 
used in the analysis of antibodies from hybridomas. This degree of 
selectivity 1s not possible with conventional antisera.
22 A 
monoc.lonal antibody to the rat LH/CG receptor has been reported, 
18 
althou_gh this antibody was used 1n immunohistochemical 
procedures, studies to access the ability of this antibody to alter 
the physiological function of the LH/CG receptor were not 
performed. Recently, a monoclonal antibody to the porcine 
testicL:Jlar LH rece_ptor was reported. 21 This antibody was also used 
for immunohistochemical procedures and was not effective 1n 
blocking ligand binding to the receptor, therefore would be of 
limited value for the study of receptor binding/ activation. 
The fundamental goal of this research was to produce 
monoclonal antibodies with specificity for e.pitope.s at or near the· 
ligand binding site of the porcine LH/CG receptor, as it is believed 
these would be most valuable for future study of the mechanism of 
receptor activation. Monoclonal antibodies specific for the porcine 
LH/CG receptor was proposed for several significant reasons: 1) 
sufficient quantities of porc•ne corpora luteal tissue used for 
receptor isolation/purification, was readily available from the 
slaugterhouse in Hatfield, Pa~; 2) the protocols for the isolation and 
purification of the LH/CG recepto.r have been previo·usly developed 
and are now routinely used in our laboratory, and most importantly; 
3) cDNA ana·lysis has revealed that the porcine LH/CG receptor gene 
sequence is greater than 94°/o identical to that of the human; 1n 
comparison to the rat, which is only 90°/o identical to the human 
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LH/CG receptor gene sequence. 23 A secondary goal of this research 
then was to assess the degree of antibody cross-reactivity between 
the porcine and human LH/CG receptor. 
In generating anitbodies specific for a ligand binding site-, 
one maJor difficulty is producing antibodies which recognize 
conformational determinants characteristic of the n_ative, rather 
than the unfolded antigen. One solution to this problem is the 
production of anti-idiotypic. antibodies which act as inverse images 
of the determinant, and therefore, may possess an acceptable 
conformation at the outset. For this reason, in addition to a direct 
immunization approach, injecting purified LH/CG receptor or 
.membrane vesicles; an alternate method, injecting hCG foll.owed by 
cyclophosphamide, was included in the immunization protocol to 
facilitate the production of anti-idiotypic antibodies to hCG. 
Cyclophosphamide attacks DNA by alkylation and cross-linking. T 
cells which mediate suppression are more vulnerable to the effects 
of cyclophosphamide than helper T cells, causing a significant 
reduction in T suppressor cell function.25 During an ongoing immune 
response therefore, the production of idiotypic antibodies is not 
suppressed, hence resulting in the increased production of 
anti-idiotypic antibodies. 25 For our application, anti-idiotypic 
antibodies produced in response to the binding domain of hCG will 
simurate a_ntibodies to the LH/CG receptor to which it binds. 
Interestingly, our success in generating monoclonal antibodies 
specifc for the ligand binding domain of the LH/CG receptor may, in 
part, be due to this immunization technique. In particular, mouse 83 
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which was sacrificed and used in the fusion procedure on 10/12/90 
had only been injected with hCG and porcine LH, yet demonstrated 
significant titer to the LH/CG receptor. Furthermore, 16 of the 23 
monoclonal antibodies selected were derived from this fusion. It 1s 
v 
proposed that the injection of the ligand, followed by cycl.o-
phosp ham ide to faci I itate the production of anti-id iotypic 
antibodies, may be a superior immunization method for the 
production of monoclonal antibodies specific for a receptor binding 
site. 
In addition to the immunization protocol, another factor 
contributing to our success in generating antibodies specific for the 
porcine LH/CG receptor binding site was the development of 
screening· techniques to specifically select antibodies which 
exhibited key functional properties. These included the ability of 
the antibody to block radiolabeled hCG binding to the receptor using 
a hCG competitive binding assay. This assay has been routinely used 
by a number of in.vestigators, 16,17,18,19,20 in order to assess the 
specificity of antibody binding to the receptor. Likewise, a 
modification of this assay was developed as a key part of the 
screening process. In addition, antibodies were selected for their 
ability to alter progesterone secretion from granulosa cells in 
culture. It is well documented that a primary function of the 
granulosa lutein cell is the synthesis and secretion of progesterone, 
in response to the binding of LH/CG to its specific membrane bound 
receptor. 1,2 Antibodies specific for the ligand binding site of this 
receptor would be expected to alter progesterone secretion 
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from granulosa cells in culture. As such, a progesterone bioass
ay 
was developed in order to screen for antibodies which had 
the 
ability to alter progesterone secretion from granulosa cells 
in 
culture. In addition to the functional criteria described above, 
only 
antibodies of the lgG subclass were selected for several reason
s 
including: 1) lgG antibodies are monomeric in structu.re and have 
higher epitope binding affinites tha11 lgM antibodies which are 
pentameric in structure, 24 2) lgG antibodies have a significantly 
lower molecular weight than lgM antibodies, 150 kDa and 900 kD
a, 
respectfully~ 25 As a result, lgG antibodies may have a great
er 
potential to reach the target reproductive. organs, a prim
e 
consideration for subsequent in vivo studies using these antibodie
s, 
and 3) easie.r, more direct methods have been developed for the 
isolation and purification of lgG antibodies. 
22 
·
24 
Subsequent to the screening/selection process, the 
results of the series of cellular assays developed prov
ide 
substantial evidence that the 23 monoclonal antibodies are spec
ific 
for epitopes at or near the ligand binding site of the- LH/CG recepto
r. 
Furthermore, that a signi·ficant degree of antibody cross-reactivi
ty 
to the human LH/CG receptor does indeed exist. The use of culture
d 
porcine and human g ranulosa cells, respectively, was of prim
e 
importance in the development of these cellular assays, (i .e the 
cellular ELISA immunoassay, the cellular hCG competitive bindin
g 
assay, the progesterone bio~ssay, and fluorescent microscop
y 
studies), as it is believed that the physiological effectiveness. of 
monoclonal antibodies specific for the ligand binding site of this 
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receptor can be assessed most accurately through. the use 
of viable. 
cells possessing intact, native receptors. As· exp~cted, eac
h of the 
23 monoclonal antibodies demonstrated significant binding
 1n the 
cellular ELISA immunoassay. More importantly, all 23 mo
noclonal 
antibodies displayed the ability to outcompete radiolabe
led hCG 
binding to the receptor, as well as the ability to alter prog
esterone 
secretion from granulosa cells in culture. The cumulative 
evidence 
from each of these cellular assays provide supportive evide
nce that 
the 23 monoclonal antibodies produced. are to the reactiv
e site of 
this receptor. In addition, the patchy membrane distributio
n of the 
LH receptor antibody reaction seen in the fluorescent m
icroscopy 
studies of the porcine and human granulosa cells in c
ulture i~ 
consistent to that seen with a direct label (ferritin LH) on isofated 
luteal cells, 31 and in electron microscopy studies
18 in which the LH 
rece.ptor antibody has been oqserved ·in patches on lutea
l surface 
. membranes. Thus, further supporting the evidence that 
these 23 
monoclonal antibodies are specific for the LH/CG receptor
. As was 
expected, the monoclonal antibodies generated against the
 porcine 
receptor did demonstrate significant cross-reactivity to the
 human 
receptor 1n all of the assays performed, ind.icating 
that a 
significant degree) ·of conservation in the ligand bind.ing site most 
likely exists between the porcine and human LH/CG recepto
r. 
Since the selection of these monoclonal antibodies was 
based on the demonstration of functional properties., th
ey most 
likely recognize native conformations of the receptor
. Such 
conformations, (i.e. antibody binding epitopes), may be easily 
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destroyed by protein electrophoresis and subsequent Western 
trarisfer/immunoblotting procedures, to demonstrate the binding of 
the specific monoclonal antibodies to the isolated receptor protein 
band. This may account for the unexpected results obtained in the 
i m mu nob Iott in g pro c e du res , as approx i mate I y o n I y 3 0 °/o of the 
monoclonal antibodies bound to the porcine receptor band, while 
none of the antibodies bound to the h u man receptor band; despite 
multiple variations of the immunoblot procedure to maximize the 
assay conditions. Furthermore, it was observed that freezing and 
thawing of the ovarian membrane extracts prior to electrophoresis 
destroyed th.e binding capacity of the receptor, such that antibodies 
previously shown to have significant binding to the receptor band in 
im·munoblotting procedures, di·d not bind. The negative results 
obtained with the human immunoblotting procedures, likewise 
probably reflect the !ability of the receptor and a significant loss 
of binding activity, as the ovarian tissue was frozen at -70;C prior 
to homogenization_/solubilization procedures and ·the membrane 
extracts also frozen at -70'C and thawed prior to electrophoresis. 
As the results of the cellular assays clearly indicate that these 23 
monoclonal antibodies specifically bind to the LH/CG receptor, the 
s u b o pt i rn a I res u I ts o f t h e W e st e r n t r a n s f e r / i m m· u n b I o tt i n.g 
procedures is interpreted as the loss of significant binding capacity 
of the LH/CG receptor in the ovarian membrane extracts, and not as 
a result of the inability of the antibod·ies to specificaily bind to the 
receptor. Interestingly, the results of the immunoblotting 
procedures indicating the !ability of receptor conformation, 
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f u rt h er v a I id ate an ·an ti -id i o t y p ·i c a p pro a c h to th e p rod u ct i o n of 
monoclonal antibodies specific for epitopes at or near the binding 
site of this receptor, as most likely a direct approach injecting 
purified receptor protein decreases the probability of antibodies to 
the native receptor binding site due to conformational instabilty. 
In summary, we have successfully produced monoclonal 
antibodies to the porcine LH/CG receptor which demonstrate 
specificity for e pit opes at o r near the I i g and bi n d i n g site, have the 
ability to block radiolabeled hCG binding and furthermore, have the 
ability to alter progeste·rone secretion from granulosa cells in 
culture. These anti bodies sho u Id prove valuable for future studies 
characterizing the structure of the receptor and the mechanism of 
receptor binding/activation in greater detail. In addition, provided 
that cross-reactivity to other mammalian species is d~mo.'nstrated, 
these monoclonal antibodies wil-1 be very useful for in vivo fertility 
studies in select animal models. In particular, antibodies classified 
as Group 1 which demonstrate an inhibitory effect on receptor 
function, such as Clone #: 36, 73, 9.8, 141, and 145 could be s~udied, 
in vivo, to determine their ability .to effectively inhibit the 
biological effect of the receptor, possibly demonstrating an 
immunocontracepti've potential. A.lternatively, antibodies classified 
as Group 2 which demonstrate the ability to stimulate the receptor, 
such as Clone #: 95 and 96, could be studied, in vivo, for their 
ab i I it y to st i m u I ate the LH/ CG receptor, 
progesterone synthesis and secretion. 
hence 
. . 1ncreas1ng 
Interestingly·, we have also shown that these monoclonal 
67 
antibodies demonstrate significant cross-reactivity to the human 
LH/CG receptor. This provides convincing evidence that the porcine 
and human receptors, in particular the binding domain of these 
receptors, most likely is very well conserved. These antibodies, 
therefore, will prove valuable for future research to elucidate 1n 
more detail receptor function and fertility control in the human. 
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ISOLATION AND PURIFICATION OF THE LH/CG RECEPTOR 
Materials 
1) 3M NaCl (total volume 500 mis) 
- NaCl 87.66g/500 mis dH20 
2) 0.5M Na P04 (total volume 200 mis, pH 7.4) 
- NaH2P04 Monobasic 3.11g/ 200 mis dH20 
- Na2HP04 Di basic 10.98g/ 200 mis dH20 
3) PBS (total volume 1 liter; pH 7.4) 
- 3M NaCL 
- 0.5M Na P04 
4) HEPES/Sucrose Buffer ( total volume 1 
- 0.27M sucrose 
- 25mM Hepes 
- 1mM EDTA 
- Penici°llin/Streptomycin (Sigma) 
51.33 mis 
20 mis 
liter; pH 7.4) 
92.3 g 
6.5 g 
10 mis of 100 mM stock 
10 mis 
(10,000UPenicillin G/ml; 
10 mgs. Streptomycin/ml 
in 0.9°/o NaCl). 
·5) 1 OX Protease Inhibitor Solution (per total volume 40 mis dH20) 
- Benzamidine 6 mg 
- TLCK-(N-alpha-p-Tosyl-L-
Lysine Chloromethyl Ketone) 
- alpha-amino caproic acid 
- leuptin 
- pepstatin 
- soybean trypsin inhibitor 
6) PMSF (1 OOmM stock in ethanol) 
- PMSF 
7 .. 2 mgs 
260 mgs 
2 mgs 
2.8 mgs 
40 mgs 
0.1742g/10 mis ethanol 
7) CHAPS Extract ( total volume 1 O mis; pH 7.4) 
- 40°/o glycerol 4 mis: pure glycerol 
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- 15mM NaP04 
- 7.SmM EDTA 
- 20 mM CHAPS 
8) 1 mM HCL (total volume 100 mis) 
- HCI (conc:12.1 M) 
0.3 mis : 0.5M NaP04 
0.75 mis : 1 OOmM EDTA 
1 ml: 200 mM CHAPS 
8.1ul/100 mis dH20 
9) 0.1 M NaHC03/ 0.5M NaCl ( total volume 1 liter; pH 8.3) 
- NaHC03 8.4g 
- NaCl 2_9.22g 
10) 0.1 M NaAc/ 0.5M NaCl ( total volume 1 liter; pH 4.0) 
- NaAc 13.61 g 
- NaCl 29.61 g 
11) 0.1 M NaHC03/ 0.5M NaCl ( total volume 1 liter; pH 9.0) 
- NaHC03 8.4g 
- NaCl 29.22g 
12) 0.2M Glycine ( total volume 1 liter; pH 8.0) 
- Glycine (anhydrous; MW 75.1) 15.02g 
13) 1 OmM NaP04/ 25°/o Glycerol ( total volum.e 1 liter) 
- 0.5M NaP04 20 mis 
- pure grade glycerol 
14) pH 7.4 Wash Buffer (total volume 1 
- Glycerol 
- 3M NaCL 
- 0.5M P04 
- 15°/o Triton X-100 
15) pH 5.5 Wash Buffer (total volume 1 
- Glycerol 
- 3M NaCL 
- 0.5M P04 
- 15°/o Triton X-100 
- Glacial Acetic Acid 
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250 mis 
liter; pH 7.4) 
250 mis 
166.66 mis 
20 mis 
3.33 mis 
liter; pH 5.5) 
250 mis 
166.66 mis 
20 mis 
3.33 mis 
1.5 mis 
16) pH 5.5 Wash Buffer/ 5mM CHAPS (total volume 50 mis) 
"" pH 5.5 Wash Buffer 48.75 mis 
~ 200mM CHAPS 1.2"5 mis 
17) pH 4.0 Elution Buffer (total volume 1 liter; pH 4.0) 
- Glycerol 252 mis 
- 3M NaCl 168 mis 
- 0.5M NaP04 
- 15°/o Triton 
- Glacial Acetic Acid 
- 200mM CHAPS 
20 mis 
3.36 mis 
1.52 mis 
25 mis 
18) 3M Tris Base ( total volume 100 mis; pH 8.3) 
- Tris Base (MW 121.1) 36 .. 33g 
19) 1 M NaCL/ 0.1 NaHC03/ 0.5°/o Triton (total volume 1 liter; ·pH 9.0) 
- 3M NaCl 100 mis 
- NaHC03 2. 77g 
- Triton X-100 1.5 mis 
20) 1 M NaCl/ 0.1 M NaAc/ 0.5°/o Triton (total volume 1 liter; pH 4.0) 
- 3M NaCl 100 mis 
- NaAc 2.7g 
- Triton X-100 1.5 mis 
* NOTE: Adjust pH with Glacial Acetic Acid 
21) 1 M NaCl/ 50mM NaP04/ 0.5°/o Triton(total volume 1 liter; pH 7.4) 
- 3M NaCl 100 mis 
- 0.5M P04 15 mis 
- Triton X-100 1.5 mis 
22) 1 OmM NaP04 (total volume. 100 mis) 
- 0.5M NaP04 2ml/100 mis dH20 
23) 5°/o BSA/PBS (total volume 100 mis) 
- BSA Sg/100 mis PBS 
24) 5mg/ml lgG in 0.1°/o BSA/PBS (stock; per 100 mis) 
- lgG O.Sg/100 mis PBS 
- 0.1 °/o BSA/PBS 0. fg BSA/100 mis PB.S 
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25) 30°10 PEG/PBS (total volume 100 mis) 
- Polyethylene Glycol 30g/100 mis PBS 
26.) 0.2°10 Triton X-100 (total volume 100 mis) 
- Triton X-100 0.2mls/100 mis dH20 
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Procedure 
1. Homogenization 
a. Collect porcine ovaries in PBS with antibiotics 
(Pen/Strep). 
b. Weigh a beaker containing 30-40 mis. of hepes/sucrose 
buffer. 
c. Excise approximately 50g of corpora luteal tissue and add 
to beaker containing buffer. 
d. Reweigh the beaker containing buffer and tissue. 
e. Add protease inhibitors (1 OXsolution). 
f. Add PMSF (100 mM stock) to 0.1 mM final concentration. 
g. Homogenize using a Dounce tissue homogenizer, 6 strokes 
using a loose-fitting pestle, pestle B. Filter through 1 
layer of gauze to remove large connective tissue sheets. 
h. Rehomogenize filtrate using a Dounce tissue homogenizer 
with a tight fitting pestle, pestle A, 20 strokes. 
1. Dilute homogenate with hepes/sucrose buffer containing 
protease inhibitors. to approximately 20-25°/o (w/v), 
approximately 200 mis total volume. 
J. Centrifuge in a Beckman J-21 M preparatory centrifuge, 
using a JA-20 rotor, at 6500 RPM for 15 minutes, (5000 
X g), in order to remove unbroken cells, large membrane 
sheets, mitochondria and lysosomes. 
k. Supernatant is removed and spun in a Beckman 
Ultracentrifuge, using a Ti-60 rotor, at 40K for 90 
minutes. 
I. The pellets were pooled and resuspended in hepes/sucrose 
buffer containing protease inhibitors to a total volume of 
100 mis, re homogenized about 10 strokes with the tight 
fitting pestle (pestle A) and recentrifuged as above, 40 K 
for 90 minutes. 
m. The final pellet is referred to as "P3" and can be frozen 
at -70'C or used immediately in the solubilization 
procedure. 
2. Solubilization 
a. To the "P3" pellet (derived from approximately 50g of 
corpora luteal tissue), add: 20 mis. CHAPS extract 
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4 mis.of protease inhibitors(1 OX) 
400 ul. of PMSF (1 OOmM stock) 
b. Adjust volume up to 40 mis with dH20. 
c. Homogenize with the tight fitting Dounce (pestle A), 40 
strokes. 
d. Sonicate for 15 seconds at a setting of 3. 
e. Incubate on ice, rehomogenizing occasionally with pestle 
A over a 45 minute incubation. 
f. Dilute with 80 mis. of solution B, final volume 120 mis. 
g. Centrifuge with Ti60 rotor 35K for 90 minutes. 
h. Supernatant, "Sol", is kept, alliquotted and frozen at 
-70'C or immediately used in the affinity gel 
chromatography procedure for the isolation of the LH/CG 
receptor. 
3. Affinity Gel Chromatography 
a .. Preparation of CnBr Sepharose for Batch Analysis: 
1. Use: 15 g CnBr 48 Sepharose 
25 mg Sigma hCG 
100-250 X 103 cpm *hCG, (See Appendix E) 
2. Swell 15g CnBr Sepharose in 350 mis 1 mM HCI for 15 
minutes. 
3. Filter by vacuum suction through a modified bottle top 
filter fitted with a 52 micron nylon screen mesh. 
4. Wash with 650 mis 1 mM HCI. 
5. Wash with 100 mis 0.1 M NaHC03/0.5M NaCl, pH 8.3. 
6. Dissolve 25 mg of Sigma hCG in 40 mis 0.1 M NaHC03/ 
0.05MNaCI, pH 8.3. 
7. Add *hCG. 
8. Add mixture from step 6 into gel, put in beaker, cover 
with parafilm and shake end-to-end at room 
temperature for 3.5 hours, on 
9. Filter suction. 
10. Wash with 750 mis 0.1 M NaAc/0.5MNaCI, pH 4.0. 
11. Wash with 750 mis 0.1 M NaHC03/0.5MNaCI, pH 9.0. 
12. Repeat steps 10 and11 twice more, totaling 3 washes 
alternating pH 4.0 and 9.0. 
13. Resuspend gel in 500 mis of 0.2M glycine, pH 8;0. 
14. Shake at room temperature for 1.5 hours. 
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15. Wash 750 mis, pH 9.0 buffer. 
16. Wash with 750 mis, pH 4.0 buffer. 
17. Leave in 250 mis pH 4.0 buffer overnight at 4'C. 
18. Wash with 2-2.5 liters cold dH20. 
19. Wash with 2-2.5 liters cold PBS, then 200 mis 1 O mM 
NaP04/25°/o glycerol. 
20. Store in 1 OmM NaP04/25°/o glycerol, 0.1 °/o Triton. 
21 . Let sit 1 week prior to use. 
b. Before use, wash CnBr sepharose with 1 liter of dH20, 1 
liter of PBS and then 200 mis of 1 OmM NaP04/25°/o 
glycerol buffer, using the modified bottle top filter 
described previously, remove gel to a 250ml glass beaker. 
c. Add approximately 40 mis of solubilized membrane prep, 
"Sol"from previous step, (i.e. homogenization/ 
solubilization procedure). 
d. Cover beaker with parafilm and mix on shaker overnight 
at 4'C. 
e. Place beaker at room temperature and mix at least 1.5 
hours on shaker." 
*NOTE: Subsequent steps ( f-o ·) done 1n the 'cold room' at 
4'C. 
f. Pour slurry into the suction device and retain drainage: 
fraction #1 
g. Put gel in beaker with 500 ml pH 7.4 wash buffer and let 
sit for 10 minutes. Suction filter: fraction #2. 
h. Wash with 350 mis pH 7.4 wash buffer.: fraction #3. 
i. Rinse out suction filter flask; add 4 mis 3M Tris,_ pH 8.5 to 
suction flask; put gel in beaker with 500 mis pH 5.5 wash 
buffer; let sit for 5 minutes. 
J. Suction filter: fraction #4. Immediately adjust pH to 
7.2-7.4 with 3M Tris. 
k. Add 3 mis 3M Tris, pH 8.5 to suction flask; wash with 350 
mis pH 5.5 wash buffer ; fraction #5. Immediately adjust 
pH to 7.2-7.4 with 3M Tris. 
I. Add 400 ul 3M Tris to suction flask; mix in suction filter 
filter wash with 50 mis pH 5.5 5mM CHAPS wash buffer: 
fraction Sa. 
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m. Add 500 ul 3M Tris to suction flask; add 50 mis pH 4.0 
elution buffer to filter. Mix by swirling filter 30-60 
seconds. Suction. Immediately adjust pH to 7.2-7.4: 
fraction #6. 
n. Repeat step "m" 4 times, collecting fractions 
#7,#8,#9,#10. 
o. Record the volumes of all fractions, remove 0.5 ml of 
each fraction and store at -70'C for aurodye protein 
assay and keep the remainder of fractions on ice for 
binding study and concentration procedure to follow. 
p. To reuse the CnBr-hCG Sepharose: 
1. Wash and put gel in 1 M NaCl/ 0.1 NaHC03 0.05°/o Triton, 
pH 9.0; approximately 300 mis for 2 hours at 4'C. 
2. Wash and put gel in 1 M NaCl/ 0.1 M NaAc 0.05°/o Triton. 
pH 4.0; approximately 300 mis overnight at 4'C. 
3. Wash and put gel in 1 M NaCl/ 50mM NaP04 0.05°/o 
Triton, pH 7.4; approximately 300 mis for 2 hours at 
4'C. 
4. Wash with: 1 liter dH20 
1 liter PBS (pH 7.4) 
200 mis 10 mM NaP04/ 25°/o Glycerol 
5. Store gel in 10 mM NaP04/ 25°/o Glycerol 0.1°/o Triton 
-at 4'C. 
q. Perform an hCG Binding Study on 'P3', 'Sol', and each of 
the fractions collected, as follows: 
1 . Label 3 tubes for each sample .to be assayed and 3 
tubes for the 'blank' : (2 tubes for the total binding 
and 1 tube for non-specific binding). 
2. To each of the total tubes add: (total volume 1 ml) 
- 830 ul 1 O mM NaP04 
- 20 ul 5°/o BSA/PBS 
- 50 ul 1-125 labeled hCG, total counts approximately-
100,000(See Appendix E). 
-100 ul of each fraction or 100 ul 10 mM NaP04 in 
'blanks' 
3. To the non-specific binding tubes add: (total volume 1 
ml) 
- 820 ul 1 O mM NaP04 
- 20 ul 5°/o BSA/PBS 
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- 10 ul cold Sigma hCG (1 mg/ml stock) 
- 50 ul 1-125 labeled hCG, total counts approximately 
100,000(See Appendix E). 
- 100 ul each fraction or 100 ul of1 O mM Na P04 1n 
'blanks'. 
4. Vortex all tubes. 
5. Incubate 14-20 hours at room temperature. 
6. Stop binding assay as follows: 
a. Add 0.2 ml of 5mg/ml lgG (in 0.1 °/o BSA/PBS). 
b. Add 0.8 ml of 30°/o PEG (in PBS). 
c. Vortex, incubate in ice for 10 minutes. 
d. Centrifuge in GPA tabletop centrifuge at 3000 
RPM for 10 minutes. 
e. Remove and disgard supernatant. 
f. Add 0.9 ml 0.2°/o Triton X-100; vortex and incubate 
in ice for 10 minutes. 
g. Add 0.6 ml 30°/o PEG; vortex and incubate in ice fo( 
1 O minutes. 
h. Centrifuge as above at 3800 RPM for 15 minutes. 
i. Remove and disgard supernatant. 
, j. Count the radioactivity in all tubes in the Beckman 
5500 Gamma counter. 
r. P·ool all of the fractions which demonstrate binding 
activity to radiolabeled hCG. 
s. Concentrate pooled fractions into a 50cc sterile conical 
tube using a Millipore Immersible CX-30; single use ultra 
filtration units- 30K molecular weight cut-off, ( 
Millipore Corp, Bedford, MA.) at 4'C, until a total volume 
of approximately 5-7.5 mis. is reached. 
t. Remove 0.5 ml of concentrated sample for Aurodye 
protein assay. 
u. Dialyze concentrated sample against 2 liters of PBS for 
4-6 hours at 4'C; discard PBS and add 2 liters of fresh 
PBS and continue to dialyze overnight. Discard PBS and 
continue to dialyze sample against dH20, 2 liter times 2, 
at least 4 hours apart, to remove salts. 
v. Remove 0.5 ml concentrated sample after dialysis for 
aurodye protein assay to follow. 
w. Purified LH/CG receptor can then be used for mouse 
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injections, or coating 96-well polystyrene plat~s (1 Oug 
protein/plate) for purified LH/CG receptor ELISA 
procedures; both procedures of which are explained in 
greater detail, to follow. 
x. Perform an aurodye protein assay on each of the fractions 
collected, as well as on the pooled sample before and 
after dialysis as follows: 
1. Prepare standards using 7 .4 pH wash buffer: 
a. Make stock BSA solution (0.01 mg/ ml pH 7.4 
buffer). 
b. Make series of standard solutions from this BSA 
stock as to I lows: 
- 20 ng/ml= 20 ul stock + 980 ul buffer. 
- 40 ng/ml= 40 ul stock + 960 ul buffer. 
- 60 ng/ml= 60 ul stock+ 940 ul buffer. 
-1 OOng/ml= 100 ul stock+ 900 ul buffer. 
- 200 ng/ml= 200 ul stock + 800 ul buffer. 
- 300 ng/ml= 300 ul stock+ 700 ul buffer. 
- 400 ng/ml= 400 ul stock+ 600 ul buffer. 
- 500 ng/ml= 500 ul stock + 500 ul buffer. 
2~ Prepare samples to be assayed: 
a. For each of the standard solutions prepared above, 
place 100 ul into an assay cuvette. 
b. For the 'blank' place 100 ul pH 7.4 wash buffer into 
assay cuvette. 
c. For each of the collected fractions, (i.e. 1-10), as 
well as the samples before and after dialysis, place 
200 ul into an assay cuvette. NOTE: if sample 
dilutions are required use only 100 ul of the diluted 
sample to be assayed. 
3. Add 800 ul of Aurodye to each cuvette to be assayed. 
4. Vortex all cuvettes well. 
5. Read the 'blank' cuvette, each of the standards, as 
well as all sample cuvettes at timed intervals, (i.e. 30 
minutes, 1 hour, 2 hours, overnight). 
6. From the calculated standard curve and the absorbance 
readings of each sample calculate the protein 
concentration. 
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SOMATIC CELL HYBRIDIZATION 
Materials 
1) lscove's Wash Media (total vo-lume 1 liter; pH 7.2) 
- lscove's Modified Delbecco's Media (Sigma) 1 vial/1 liter 
- NaHC03 3.2g 
- Pen/Strep 10 mls/1 O,OOOU/ml 
2) lscove's Growth Media (total volume 1 liter; pH 7.2) 
- lscove's Wash media 1 liter 
- Fetal Bovine Sera 100 mis 
3) HAT Media ( total volume 500 mis) 
- lscove's Growth Media 500 mis 
- Hypoxanthine-Aminopterin-
Thymidine (Sigma) ; final 
concentration 100uM, 0.4uM, 
and 16uM, respectfully 1 bottle: SOX stock 
4) HT Media (total volume 500 mis) 
- lscove's Growth Media 500 mis 
- Hypoxanthine-Th9midine (Sigma) 
final concentration 1 OOuM 
and 16uM, respectfully 1 bottle: SOX stock 
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Procedure 
1. Preparation of the myeloma cells 
lntraspecies fusions are more successful than 
cross-species fusions, primarily due to the rapid loss of 
chromosomes in heterokaryons making it difficult to isolate stable 
hybridomas. For this reason, the Sp2/0-Ag 14 myeloma cell line, 
derived from Balb/C mice were used in the fusion technique. Cells 
of this line possess 72 chromosomes and do not produce endogenous 
immunoglobulins. 
Three days before cell fusion, the myeloma cells were 
seeded at a concentration of approximately 5 X 104
 cells/ml in 
lscove's Modified Delbeccos media supplemented with Pen/Strep, 
and 10°/o FBS, (growth media or GM), into 25-ml flasks. This results 
in a log growth phase in which cells have optimum fusion 
properties. 
On the day of the fusion, the myeloma cells were gently 
agitated from the 25 ml flasks and pooled into 50 cc sterile conical 
tubes. Cells were centrifuged at 900 RPM for 10 minutes. The 
culture supernantant was removed and the cell pellet was gently 
resuspended in 15 mis. wash media, (lscove's Modified Delbecco's 
media, without FBS, but containing Pen/ Strep). The cell 
suspensions were centrifuged at 1150 RPM for 8 minutes. This wash 
was repeated 3 times. An alliquot of cells was counted with a 
hemacytometer. 
2. Preparation o.f Spleen Cell's 
On the day of the fusion, the mouse demonstrating the 
highest anti-LH/CG R antibody titer was sacrificed and the spleen 
excised into a sterile petrie dish containing lscove's wash media. 
The spleen was carefully minced using sterile forceps and gently 
aspiratep up and down into a 10cc sterile syringe fitted with 
needles of increasing gauge size, (i.e. 20g, 18g,and 16g), to gently 
break up the. clumps. The mincate was then filtered through a 52 uM 
sterile ny·lon screen into a sterile 50 ml conical tube. The spleen 
cells were then transfered to a sterile 15 ml conical tube and spun 
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at 1200 RPM for 1 O minutes. Cells were washed 3 times in lscove's 
wash media and a cell count was performed using a hemocytometer. 
3. Fusion Technique 
Spleen cells were mixed with myeloma cells at a ratio of 
5:1 in a sterile 50 ml conical tube, and spun at 1100 RPM for 1 O 
m_inutes. All supernatant media was removed from the cell pellet. 
The tube containing the cell pellet was placed in a 37'C water bath 
and additions were made in the following sequence: 
Addition* 
1.0 ml PEG** 
Gently stir 
1.0 ml GM 
1.0 ml GM 
8.0 ml GM 
Time (min) 
0-1 
1-2 
2-3 
3-4 
4-·6 
** 1.0 ml PEG added per 1.6 X 108 spleen cells used in fusion. 
* All additions were done in a dropwise manner while gently 
stirring. 
The tube containing the cell mixture was then spun at 750 
RPM for 6 minutes and the PEG supernant was disgarded. The ce.11 
pellet was then resuspended in a total volume of: (1 O mis per every 
10-15 million spleen cells used). 96-well microtiter plates were 
seeded at 1 OOul/well and plates were incubated at 37'C overnight. 
4. Hybridoma Culture 
Following fusion of splenocytes and myeloma cells, several 
ce II types po p u I ate th e m ix tu re , with th e d es i- red 
myeloma-splenocyte hybrid being a minor population of cells. ·It is 
therefore necessary to enrich for the myeloma-splenocyte hybrid by 
selecting against the other cells. This is accomplished by cu.lturing 
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the cells 1n HAT (Hypoxanthine- Aminopterin- Thymidine) 
supplemented media. Aminopterin, a folic acid analog, blocks de 
nova synthesis of thymidylate and purine nucleotides. Cells with 
tu nctio nal hypoxanth in e-g u an i ne-phospho ribosyl transferase 
(HGPRT) and thymidine kinase (TK) enzymes can synthesize 
necessary nucleotides from exogenous hypoxanthine and thymidine. 
The myeloma cells lines used to generate hybridomas however, are 
mutants in either HGPRT or TK or both. Consequently, myeloma cells 
alone will not grow in HAT supplemented media. Since splenocytes 
have a very short lifespan in culture, the only cells which continue 
to grow and proliferate in HAT supplemented media are the 
hybrido mas. 
The cells are grown in HAT supplemented media for 7-14 
days and are then grown in HT media for at least a week prior to 
transfer to complete media,(lscove's growth media). Cell culture in 
HT media provides adequate ex.ogenous sources of hypoxanthine and 
thymidine while diluting the remaining intracellular aminopterin. 
The schedule for refeeding the cell cultures was as follows: 
TIME(day) Type of Media Protocol 
0 
1 
2 
3 
4 
7 
1 1 
Compete 
HAT 
HAT 
HAT 
HAT 
HAT 
HT 
Plate the fused cells at' 1 OOul/well 
Add tOOul HAT media to each well 
Aspirate 1 OOul of spent media and 
replace with 1 OOul of HAT media* 
Aspirate 100ul and refeed with 100ul 
Aspirate 100ul and refeed with 100ul 
Aspirate 1 OOul and· refeed with 100ul 
Aspirate 100ul and refeed with 100ul 
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14 ** 
18** 
22** 
HT 
HT 
HT 
Aspirate 1 OOul and refeed with 1 OOul 
As.pirate 100ul and refeed with 100ul 
Aspir~te 1 OOul and refeed with 1 OOul 
* An 18 gauge needle was attached to a vacuum source and was 
used to aspirate the medium from each well. If the needle is placed 
directly to the bottom of the well, approximately 1 OOul will be 
removed. 
** Medium was assayed for antibody if the majority of the wells 
were greater than 50-75°/o confluent. 
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SCREENING TECHNIQUES 
Materials- ·Appendix C 
1) 1 °/o BSA/PBS (total volume 100 mis) 
- BSA 1g/100 mis PBS 
2) PBS/ 0.05°/o Tween-20 (total volume 1 liter; pH 7.4) 
- PBS 1 liter 
- Tween-20 0.5 mis 
3) Goat Anti-Mouse lgG-HRP in 2°/o BSA/PBS (per 10 mis ) 
- 2°/o BSA/PBS 10 mis 
- Goat Anti-Mouse lgG-
Horse Radish Peroxidase 
Conjugate (Zymed, Inc., 
catalog # 62-6620) 5 ul 
4) Citrate Phosphate Buffer ( total volume 1 liter: pH 4.25) 
- Citric Acid (monohydrate) 10.5g 
- NaP04 (dibasic) 1 O.Og 
5) MEM/Hank's Media ( total volume 1 liter; pH 7.3) 
- MEM/HBSS and non-Essential 
Amino Acids (Sigma) 
- Hepes (sodium salt) 
- Gentamycin 
- Fungizone 
- BSA (low endotoxin ;low fat) 
- Penicillin/Streptomycin 
- Glucose 
- NaHC03 
1 bottle 
2.6g 
70mg 
1 ml of 1 OOOX stock 
1g 
10 mis (1 O,OOOU/ml) 
0.8g 
0'.35g 
6) 15°/o Histopaque/MEM-Hank's (total volume 1 O mis) 
- Histopaque(density 1.119) 1.5 mis 
- MEM-Hank's 8.5 mis 
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7) DMEM/Ham's F-12 (total volume 1 liter) 
- DM E/Ham's F-12 (Sigma) 
- Insulin 
- Gentamycin 
- Penicillin/Streptomycin 
- BSA (low fat, low endotoxin) 
- NaHC03 
1 vial 
1 mg dissolved 1n 
200ul 0.1 M HCL 
35 mgs 
10 mls(10,000 U/ml) 
1g 
1.2g 
8) CMPOC-Culture Media for Porcine Ovarian Cells (per 100 mis) 
- DMEM/Ham's F-12 1·00 mis 
- FBS (low lgG) 10 mis 
- FSH 10 ul ( 1 mg/ml stock) 
- Amphoteracin 50 ul (1 OOOX stock) 
- LDL 12.5ul(40mg/mlstock) 
9) CMPOC without FSH (per 100 mis) 
- DMEM/Ham's F-12 
- FBS (low lgG) 
- LDL 
- Amphoteracin 
10) CM POC/Transferrin Media (per 100 mis') 
- DMEM/Ham's F-12 
- FBS 
- LDL 
-Transferrin 
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100 mis 
10 mis 
12.5ul(40mg/mlstock) 
50 ul (1 OOOX stock) 
100 mis 
5 mis 
25u I ('20 mg/mlstock) 
0.5 mg 
Procedure 
1. ELISA 
1) 96-well polystyrene plates (Corning) were coated with antigen; 
as multiple types of ELISA assays were developed and used in 
the screening procedures, several types of ELISA plates were 
prepared, as described below: 
a) Purified LH receptor coated plates. Porcine LH/CG 
receptor was isolated and purified according to the 
aforementioned procedure. Following binding activity 
studies and protein assays, a total of 1 Oug of purified 
LH/CG/receptor was resuspended in 10 mis PBS (ph 7.4) 
and 1 OOul/well was added to the 96-well plate. A 
minimum of an overnight incubation at 4'C was allowed 
in order to ensure sufficient binding of the antigen to 
the plate prior to ELISA assay. Furthermore, these 
antigen coated plates were found to. be stable at 4'C for 
several months. 
b) Porcine corpora luteal membrane vessicle coated 
plates. Homogenized/solubilized porcine corpora luteal 
membrane prep ("P3"), as described in the receptor 
isolation procedure, was washed in HEPES/sucrose 
buffer, and spun in the JA-14 rotor at 11,000 RPM for 15 
minutes. The supernatant was removed and the wash 
repeated. A 1 to 20 dilution of the membrane vessicle 
pellet was made in PBS (ph7.4), mixed well, and 
50ul/well added to the 96-well plates. A minumum of 
an overnight incubation was allowed in order to ensure 
membrane vesicle attachment to the plates. 
c) Goat anti-mouse lgG coated plates. 1 O?ul of goat anti-
mouse lgG, gamma chain specific, (Zymed,lnc .. , So.San 
Fransisco, total protein 0.75mg/ml, catalog# 
62-6600), was diluted in 40 mis. PBS (ph 7,4) and 
1 OOul/ well added to 4, 96-well plates. Plates were 
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covered an incubated at 4'C overnight prior to use in 
order to allow antibody attachment to plates. 
IMPORTANT: When performing an lgG sandwich assay to 
quantitate the amount of lgG present in culture supernatat 
or ascites, it is critical to run a series 
of anti-mouse lgG standards of known concentration by 
which to compare unknown samples. For this purpose, 
serial 2-fold dilution of purified mouse lgG, (Zymed 
Inc., So.San Fransisco, catalog# 90-6551) are prepared 
in 2°/o BSA/PBS and are run in parallel with the assay. 
The specific concentrations used as known standards 
are serial 2-fold dilutions ranging from o·.156 ug/ml to 
3.125 ng/ml. The absorbance values of these known 
standards are then used to assess the lgG concentration 
in the unknown sample. 
NOTE: For each of the ELISA variations described above, with the 
exception of plate preparation, all subsequent steps of the 
procedure remain the same and are as follows. 
2) Plates were washed with distilled water and blotted dry. 
3) 150ul/well of1 °/o BSA/PBS (ph7.4) was added as a blocking agent 
in order to block all non-specific binding sites . 
. 4) Plates were covered and incubated at 37'C for 1 hour. 
5) The BSA/PBS was removed and all wells were washed with PBS/ 
0.05°/o Tween 20, 6X, blotting extensively between each wash. 
6) Cell culture supernant/ascites fluid etc. to be tested was added 
(ie. mouse antibodies specific for the antigen coating the plate 
will bind to the solid phase, this is referred to as our primary 
antibody). 
7) Plates were covered and incubated at 37'C for 1 hour. 
8) All wells were extensively washed, as described above .. 
9) A 1 :2000 dilution of goat anti-mouse lgG/Horse Radish Peroxi-
dase conjugate was made in 2°/o BSA/PBS, and 1 OOul/well added. 
(This antibody will bind to any mouse lgG antibody now attached 
to the plate,and is referred to as the secondary antibody). 
to) Plates were covered and incubated at 37' C for 1 hour 
11) A.II wells were extensively washed as described above. 
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12) The addition of substrate and the absorbance reading 
constitutes the final step of the ELISA procedure. The substrate 
of choice for our assays was 2-2'-Azino-bis-(3-ethylbenzthia 
zoline- 6)-sulfonic acid, (ABTS), (Sigma), dissolved in a pH 4.25 
citrate phosphate buffer (1 mg dissolved in 20-25 ml buffer) to 
which H20 2 (1 Oul) was added.The horse radish peroxidase 
enzyme bound to the secondary antibody will then convert 
colorless substrate into a colored (green) product. The degree of 
color development in a particular well will be monitored by its 
absorbance at 405nm using the automated ELISA reader and will 
be a direct indication of the amount of primary antibody 
originally bound to the plate. 
2. HCG INHIBITION ASSAY 
1) Cell culture supernatant/ascites fluid were incubated with 
membrane vessicles derived from porcine corpora luteal tissue 
in 96-well plates at 37' for 2 hours und(3r aggitating conditions, 
(antibodies to the LH/CG receptor will bind to the intact 
receptor present on the vessicles). 
2) 1251-labeled HCG ( 100,000 counts/25ul), (See Apendix E),was 
added to each well of the membrane preparations and incubated 
at 37'C for 2 hours, also under aggitating conditions. 
3) Filter paper discs, cut specifically to fit the wells of a 96-well 
plate containing small pores on the bottom of each wen to allow 
a vacuum suction, were blocked with 1°/o BSA/PBS (pH7.4) and 
incubated for 1 hour at 37'C. 
4) The blocking solution was suctioned through the wells and the 
radioactive membrane preps were transferred to the 96-well 
plate lined with filter paper discs using a 12-channel multiple 
pi petter. The incubation wells were washed with 100 ul/well 
PBS/0.2°/o BSA, and the wash transferred to the 96-well plate 
and suctioned through using the vacuum manifold. The samples 
and wash were not suctioned until all of the samples and washes 
were transferred. The membrane preps were washed twice, 200 
ul/ PBS/BSA each wash in order to remove all excess 
radioactivity not bound to the membrane. 
5) Total radioactivity of each filter paper dies, containing the 
membrane fraction with bound radiolabeled hCG, was me.as.ured 
using the gamma counter. 
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NOTE: We would expect in this assay that antibodies specific for 
the binding site of the LH receptor will inhibiJ the subsequent 
binding of radiolabeled hCG to the receptor and thus show 
decreased radioactivity when measured in the gamma counter. 
3. IN VITRO BIOASSAY FOR PROOESTERONE PRODUCTION 
1. Tissue collection/ Processing 
a. Pig ovaries containing follicles were collected at the 
slaugtherhouse in Hatfield, Pa. and kept in ice cold 
MEM/Hank's media, containing antibiotics. 
b. After transport back to the laboratory, each ovary was 
washed 2 times in 70°/o ethanol, 2 times in MEM/Hank's 
and then stored in MEM/Hank's until all of the ovaries 
had been washed. (NOTE: Wash steps and air subsequent 
steps were performed in a sterilized table top hood, in 
order to minimize contamination.) 
c. Each follicle was punctured using a syringe fitted with 
a16g needle , aspirated and flushed several times. 
Follicular contents were pooled into 50cc sterile 
conical tubes. 
d. The follicles from approximately 20-30 ovaries were 
punctured in this fashion, yielding approximately 120 
mis. of cell suspension. 
e. To remove interfering ABC's, each 30 mis. of follicular 
cell· suspension was overlayed on a 7-10 ml. cushion of 
histopague (density 1.119), in sterile 50cc conical 
tubes, (i.e. a total of 4 tubes were used). 
f. Tubes were spun in a GPA tabletop centrifuge at 1300 
RPM for 30 minutes, at room temperature, with no brake. 
g. The granulosa cells were removed from the interface 
between the histopaque and the media, and pooled into 1 
sterile 50cc conical tube. 
h. Cells were resuspended in appromimately 42 mis. of 
MEM/Hank's media, mixed well. 
i. The follicular cell suspension was divided into 2, 50cc 
sterile conical tubes and each was underlayed with 8cc 
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of a 15°/o solution of histopaque (density 1.119) in 
MEM/Hank's. 
j. Tubes were spun at 850-900 RPM for 5-10 minutes, no 
brake. 
k. Pellets were pooled into a 15cc sterile conical tube and 
washed with MEM/Hank's media, spun at 850 RPM for 10 
minutes. This wash was repeated 3-4 times. 
I. Follicular cell pellet was resuspended in CMPOC media, 
immediately large clumps will form. 
m. Spin at 800 RPM for 5-10 minutes. 
n. Break up the clumps by gently pipetting up and down. 
o. Cells were plated out, 1 OOul/well, into 96 well plates 
such that the density/well was approximately 25°/o 
confluent. An additional 1 OOul of CMPOC media was 
added to each well. Alternatively, cell suspension could 
be frozen in an equal volume of DMSO/FBS freezing 
solution, and stored at-70'C until use. 
2. Granulosa Cell Culture 
a. Porcine granulosa cells were cultured in supplemented 
culture media for porcine ovarian cells, (CMPOC), 200 
ul/well. 
b. Every 2 days150ul of media was removed from each well 
using a vacuum flask and a 1 cc syringe fitted with an 
18g needle, and replaced with fresh culture media. 
c. When cell density reached half to full confluency, 
approximately day 7, all CMPOC media in the individual 
wells was removed, as described above, and replaced 
with 200ul/well CMPOC media without FSH. The cell 
cultures were incubated at 37'C for 36-48 hours. 
3. Progesterone Bioassay 
a. All of the culture media was removed from each well 
and 150ul/well CMPOC/trarisferrin media was added. 
b. In addition, SOul of a 1:100 dilution of each monoclonal 
antibody ascites fluid was added to individual wells, in 
duplicate. Control wells, (i.e. - antibody, +hCG; 
-antibody, -hCG) received SOul additional media. 1 
c. Cell cultures were incubated at 37'C for 2 hours. 
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d. 50ul hCG/CMPOC/transferrin media; (250ng/ml), was 
added to one of each pair of monoclonal antibody 
cultures; the other receiving 50ul CMPOC/transferrin 
media. 
e. Cell cultures were incubated at 37'C and at timed 
intervals (i.e. 2 hours, 4 hours, 6 hours,etc.), 50ul culture 
media was removed from each well into a sterile 
96-well microtiter plate and frozen at -20'C until 
assayed for progesterone content with a RIA procedure. 
4. RIA Procedure for progesterone 
a. Radioimmunoassay procedure for progesterone was 
performed using the Coat-a-Count assay kit, (Diagnostic 
Products Corporation, Los Angeles, CA). The procedure 
in brief is as follows: 
b. Label 2 plain (uncoated) 12 X 75mm polypropylene tubes 
T and NSB (nonspecific binding) in duplicate. 
c. Label 14 Progesterone Antibody-Coated tubes A-G, (i.e. 
0 ng/ml to 40 ng/ml, respectfully), in duplicate. Label 
additional antibody-coated tubes for samples to be 
assayed. 
d. Pipette 100 ul of the O calibrator A into the NSB and A 
tubes, and add 1 OOul of each of the callibrators B 
through G into the correspondingly labeled tubes. Pipet 
100 ul of each sample into the tubes prepared. 
e. Add 1.0 ml of buffered 125-1 Progesterone (yellow) to 
every tube. Vortex. 
f. Incubate for 3-4 hours at room temperature, or 1 hour at 
37'C for maximum sensitivity. 
g. Aspirate thoroughly. 
h. Count for 1 minute in the gamma.counter. 
L Calculate the standard curve by plotting the 
counts/minute by the known progesterone 
concentrations of the calibrators on semi-log graph 
paper. The concentrations of the calibrators are as 
follows: 
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Calibrators ng/ml nmol/L 
A 0 0.0 
B 0.1 0.3 
C 0.5 1.6 
D 2.0 6.4 
E 10.0 31.8 
F 20.0 63.6 
G 40.0 127.2 
J. Calculate the progesterone concentration of each sample 
from the standard curve established for that assay. 
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CHARACTERIZATION OF SELECT MONOCLONAL ANTIBODIES 
Materials 
1) Acrylamide Solution (total volume 100 mis dH20) 
- Acrylamide 30g 
- Bisacrylamide 0.8g 
2) 3M Tris (total volume 100 mis; pH 8.9) 
- Tris base (Mal Wt. 121 .1) 36.3g/100 mis dH20 
3) 10°/o SOS (per 10 mis) 
- sos 1 g 
4) 2.5M Sucrose (total volume100 mis) 
- Sucrose 85.6g/100 mis dH20 
5) 2.5°/o Ammonium Persulfate (total volume 4 mis) 
- Ammonium Persulfate 0.1 g/4 mis dH20 
6) 0.5M Tris (totalvolume 1-00 mis; pH 6.7) 
- Tris base (MW 121 .1) 6.057g/100 mis dH20 
7) Running Buffer (5X stock; total volume 
- Tris base 
- Glycine 
- sos 
8) 5X Protein Standard Solution 
- Myosin 
- Phosphorylase b 
- B-galactosidase 
- Albumin (Bovine) 
- Carboxylase 
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1 liter; 
30g 
144g 
5.0g 
pH 8.5-8.8) 
9) Western Transfer Buffer (total volume 1 liter; pH ·7.5) 
- Glycine (192mM) 14.4g 
- Tris-HCI (25mM, MW 157.6) 3.94g 
10) Goat Anti-Mouse lgG-Alkaline Phosphatase (1:1000 dilution
) 
- PBS 10.0 mis 
- Goat Anti-Mouse -
Alkaline Phosphatase ( Zymed, 
Inc., catalog # 62-6622) 10 ·u1 
11) NBT Buffer (total volume 500 mis) 
- AMP (50mM) 
- MgCl2 (SmM) 
- ZnCl2 (1 OuM) 
12) BCIP : (1 OOX Stock) 
BCI P (5-Bromo-4-Chloro-
3-lndolyl Phosphate 
*Wrap in foil; light sensitive 
l3) NBT/BCIP Substrate 
- NBT (Nitro Blue Tetrazolium) 
- NBT buffer 
- BCIP 
2.63g 
0-.51g 
soul of 1 OOmM stock: 
(0.1363g/1 Omls) 
2 mgs/1 OOul DMSO 
4.0 mgs 
20 mis 
200 ul (1 OOX stock) 
14) So/o Non-fat Dried Milk in PBS (total volume 100 mis) 
- Non-fat dried milk Sg/1 OOmls PBS 
*Note: heat tq 65'C for 1 hour prior to use 
t5) Goat Anti-Mouse lgG-Hbrse Radish Peroxidase Solution 
- Goat Anti-Mouse lgG 
~HAP (Zymed, Inc.) Sul/10 mis PBS 
16) HBSS plus Calcium (total vol·ume 1 liter; pH 7.3) 
- 10 mM HEPES 2.6 g 
- 2 mM CaCl2 0.5 mis of 1 M s
tock 
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- 0.1 °/o BSA 
- Pen/Strep 
17) Tris Buffer (total volume 1 liter; pH 
- 10 mM Tris Base 
- 10 mM NaCl 
- 10 mM MgCl2 (6 H20) 
- Mercaptoethanol 
1g 
10 mis.( 10,000 U/ml) 
7.0) 
1.21' g 
o.·5a4 g 
2.03 g 
0.7 mis (100°/o sol'n) 
18) 4-Methylumbilleryl B-0-galactoside 1n Tris buffer 
(total vol.25mls) 
19) 
- 4-Methylumbilleryl B-D-galactoside 1 mg 
- DMSO 1 ml 
- Tris buffer 24 mis 
* Dissolve substrate in DMSO, then add to Tris buffer 
Diethanolamine buffer ( 
- 1 M Diethanolamine) 
- 5 mM MgCl2 
* Add p-Nitro Phenyl 
total volume 1 liter) 
105.14 g 
1.015 g 
Phosphate 1 mg/ml DEA buffer 
100 
Procedure 
1. Antibody Typing Assay 
.a. Coat 96-well microtiter plate, (Corning Inc.) with goat 
anti-mouse, (gamma chain specific), as follows. Add 27 ul 
of goat ant- mouse lgG, (Zymed Inc., So. San Francisco, 
catalog# 62-6600, total protein 0.75 mg/ml), to 10 mis 
PBS, (pH 7.4). Mix well and alloquot 100 ul/well. 
b. Place plate at 4'C overnight to allow sufficient binding of 
the antibody to the plate. 
c. Add 150 ul/well of a 1 °/o BSA/PBS solution to each well and 
incubate at 37'C for 1 hour. 
d. Wash wells with PBS 3 times, blotting between washes. 
e. For each monoclonal antibody to be typed, add 100 ul/well of 
hybridoma cell supernatant, to each of 4 wells. Incubate 
plate at 37'C for 1 hour. 
f. Wash plate with PBS/0.05°/o tween-20 6 times, blotting 
between washes. 
g. Prepare lgG subclass-specific secondary antibody conjugates 
as follows. Prepare a 1 :500 dilution for each secondary 
antibody, (i.e. rabbitt anti-mouse lgG1 /alkaline phosphatase, 
rabbitt anti-mouse lgG2a/alkaline phosphatase, rabbitt 
anti-mouse lgG2b/alkaline phosphatase, rabbitt anti-mouse 
lgG3/alkaline phosphatase) in PBS/2°/oBSA. 
h. Add 100 ul/well of each of the 4 different secondary 
antibody subclasses to specific wells of each monoclonal 
antibody, (i.e. each monoclonal antibody will be typed against 
4 subclases of lgG). Incubate for 1 hour at 37'C. 
i. Wash plate as descibed above. 
j. Prepare substrate for alkaline phosphatase as. follows. 
Dissolve 10 mg of p-Nitrophenyl Phosphate in 10 mis of 1 M 
DEA/ MgCI buffer. Add 100 ul/well. 
k. Read absorbance values of all wells in the ELISA plate reader 
at an aborbance wavelength of 405 nm. 
2. Granulosa Cellular ELISA 
a. Porcine granulosa cells were cultured in CMPOC media in 
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96-well plates, total volume 200 ul/well. The culture media 
was aspirated, using a 1 cc syringe fitted with an 18g needle 
attached to a vacuum flask, and replaced with·200 ul/well 
fresh media every 2 days until the cell density reached near 
confluency. 
b. The media in each well was aspirated and replaced with 100 
ul/well of a 1 :50 dilution of specific antibody in HBSS/1 °/o 
BSA. The control wells received only HBSS/1 °/o BSA. 
c. Cell cultures were incubated at 37'C, without CO2, for 1-1.5 
hours. 
d. The media in each well was aspirated and cell cultures were 
gently washed 3-4 times with HBSS/1 °/o BSA, 200 
ul/well/wash, gently aspirating between washes. 
e. Goat anti-mouse lgG/B-galactosidase, (Southern 
Biotechnology Inc., catalog# 1030-06), 1 :200 dilution in 
HBSS/1 °/o BSA, was added to all wells, 100 ul/vyell. Control 
wells received HBSS/1 °/o BSA media. 
f. Cell cultures were incubated at 37'C, without CO2, for 1 hour. 
g. The media in each well was aspirated and washed as 
described above. 
h. 1 mg. of B-galactosidase substrate, 4-Methylumbelliferyl 
B-0-galactoside, (Sigma catalog# M-1633), was dissolved 
in 1 ml of dimethyl sulfoxide and then addded to 24 mis of 
Tris buffer. 125 Lil/well of this substrate solution was added 
to each well. Cell cultures were incubated at 37'C, without 
CO2 for 30 minutes. 
i. 100 ul supernatant was re·moved from each well into a 
fluorescent microtiter plate and an equal nolume of 1 M 
glycine was added to each well. 
j. Absorbance values were read in a Fluoroskan II, fluorescent 
plate reader, ( Flow Laboratories Inc., McLean, Virginia), at 
exc.itation wavelength 355 nm. and emission wavelength 460 
nm. 
3. Cellular Radiofabeled HCG Competitive Binding Assay. 
a. Porcine granulosa cells were cultures in CMPOC media, in 
96-well plates. The media was aspirated and replaced every 2 
days until the cell density reached near confluency, as 
described for the cellular ELISA procedure. 
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b. The media from each well was aspirated and replaced with 
100 ul/well of a 1 :25 dilution of specific antibody in 
HBSS/1 °/o BSA. The 'total' control wells received 100 ul/well 
of HBSS/1 °/o BSA alone and the 'non-specific' control wells 
received 50 ul/well of HBSS/1 °/o BSA + 50 ul/well of excess 
cold hCG (1 mg/ml). 
c. Cell cultures were incubated at 37'C, 
without CO2, for 2 hours. 
d. Radiolabeled hCG was added to each well, 25 ul/well (total 
counts approximately 125,000. 
e. Cultures were incubated for 3 hours at 37'C, without CO2. 
f. The media was aspirated from each well and the wells were 
washed gently with HBSS/1 °/o BSA 3-4 times, 200 
ul/well/wash, aspirating between each wash. 
g. 50 ul/well of distilled water+ 50 ul/well of 2N NaOH was 
added to each well. The contents of each well were absorbed 
onto a sterile cotton swab and the swabs were placed in 12 X 
75 glass tubes. The total radioactivity of each tube was 
counted in the Gamma counter, (Beckman Gamma 5500 ). 
4. Fluorescent Microscopy Studies 
a. Porcine granulosa cells were grown in 8-chamber covered 
slides, 400 ul CMPOC media/well. The media was aspirated 
and replaced every 2 days until cell density reached near 
confluency, about 7-10 days. 
b. Culture media was replaced with CMPOC media without FSH, 
400 ul/well, and cultures were incubated 24-48 hours. 
c. 8 ul/well of specific ascites fluid was added to individual 
wells, (total antibody dilution 1 :50). 
d. Chamber slides were incubated at 4'C overnight in a sealed, 
gassed chamber in order to minimize internalization of the 
antibody/receptor complex. The following day, the cell 
cultures were incubated at 37'C for 1 hour to ensure 
maximum binding. 
e. All media was aspirated from each well and the wells were 
washed 3 times with Hank's Balanced Salt Solution (HBSS), 
to remove excess unbound antibody. 
f. 250 ul/well of anti-mouse lgG TRITC conjugate, (Sigma), 
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(1 :200 dilution in HBSS/1°/o BSA), was added to all wells and 
slides were incubated at room temperature for 4 hours in a 
sealed, gassed chamber. 
g. Slides were washed as described above. 
h. CMPOC media was added to each well prior to observation 
under the fluorescent microscope, (Olympus BH2 
Epifluorescent microscope). 
5. Western Transfer/ lmmunoblot Procedure 
a. SOS-PAGE 
1. 7.5°/o acrylamide gels were prepared as follows: 
- MIX: acrylamide solution 9.3 mis. 
H20 18.6 mis. 
3.0 .M Tris, pH 8.9 
10°/o so·s 
2.5 M Sucrose 
4.7 mis. 
0.19 mis. 
3.75 mis. 
- Filter through Whatman #1 filter and degas with vacuum 
suction 3-5 minutes. 
- ADD: TEMED 0.0375 mis. 
2.5°/o Amm. Persulfate 0.75 mis. 
- MIX WELL and pipette into assembled mini gel apparatus. 
- Immediately overlay a few drops of dH20 on each of the 
gels with a pipette to help level and smooth the gel 
surface. 
- MIX: acrylamide solution 
H20 
0.5 M Tris, pH 6.7 
10°/o sos 
1.25 mis. 
8.31 mis. 
1.6 mis. 
0.125 mis. 
- Filter and degas as described above. 
- ADD: TEMED 0.0063 mis. 
2.5°/o Amm. Persulfate 1.25 mis. 
- Gently remove dH20 overlaying the resolving gels by 
carefully inverting the apparatus. 
- Pipette the stacking gel on top of the resolving gel, 
.completely filling the gel units. 
- Insert combs into each gel and allow to solidify a 
minimum of 1 hour. 
2. Gently dissemble pouring gel apparatus, carefully wash 
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off the glass plates and backings of each gel, and set up 
individual gel units on the electrophoresis chambers. 
3. Remove combs and wash out wells with dH20 and then 
with running buffer, suctioning out wash solution with a 
10 ml. pipette and an 18g needle between washes. 
4. Prepare standard solution: 
- To 20 ul of a 5X stock solution of mixed standards, 
(prepared and frozen at -20'C in 20ul alloquots), add 80 
ul dH20. Mix well and add 50 ul/gel to standard lane. 
5. Prepare protein: 
- Dilute 30-50ug of protein prep in a total volume of 
400ul dH20/gel. Add 1 OOul of protein solvent 
solution/gel. Mix well and add 500ul/gel 
6. Fill electrophoresis chambers with running buffer. 
7. Attach electrophoresis units to cooling device. 
8. Attach power supply, (Electrophoresis Power Supply EPS 
500/400, Pharmacia) to electrophoresis units. 
9. Turn power supply on and adjust voltage to 1 OOV and 
mAmp to 20. 
10. Once protein solvent ·line is down to the resolving gel, 
approximately 30-45 minutes, adjust voltage to 185v and 
mAmps to 35. 
11. Run proteins until the tracking dye is approximately 1 cm 
from bottom of the gel. 
12. Turn power supply off and dissemble unit. 
13. For each gel which was run, carefully remove glas·s plate, 
remove stacking gel with a rubber spatula, and nick the 
bottom right-hand corner of the gel. Pry the gel off into 
an individual trough of Western transfer buffer, in 
preparation for the transfer procedure. 
b. Western Transfer Procedure 
NOTE: The LKB 2117 Multiphor II Electrophoresis System, 
LKB Produkta AB, (Bromma, Sweden) was used for the 
Western Transfer procedures. 
1. Soak _graph_ite plates with dH20. Pour off excess water 
and blot dry. 
2. Soak nitrocellulose paper ( S &SNC paper, Schleicher and 
Schuell, Inc., Keene, NH.; BA85, Pore size 0.45 uM, catalog 
# 40-21640) in Western transfer buffer for15 minutes. 
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3. Soak 6 filter papers (all filter papers used are the same 
size as the gel) in Western transfer buffer and carefuly 
lay one on top of the other on the bottom graphite plate. 
If bubbles form between the layers of filter paper, gently 
press them out. 
4. For first transfer unit, soak an additional 3 filter papers 
in Western transfer buffer and place them on top of the 
previous 6. 
5. Carefully place the nitrocellulose paper on .top of the 
filter paper. 
6. Place the gel on top of the nitrocellulose, backing side 
down. 
7. Soak an additional 3 filter papers in Western transfer 
Quffer and carefully layer on top of the gel. 
8. If additional gels are to be transferred, soak a piece of 
dialysis membrane, only as big as the gel, and place on 
top of the filter paper. 
9. For each additional gel to be transferred repeat steps 4-8 
above, ( i.e. 3 filter papers, nitrocellulose, gel, 3 filter 
papers, dialysis membrane). 
10. After the last transfer unit has been assembled omit the 
dialysis membrane, (i.e. end with the 3 filter papers), and 
add an additional 6 filter papers, first soaked in Western 
transfer buffer. 
11. Blot the excess distilled water off the top graphite plate 
and carefully place on top of the assembled transfer 
units. 
12. Plug the. electric cords from the graphite plates into 
semi-dry transfer unit, and place lid securely on top of 
the unit. 
13. Plug transfer unit into power supply, (Model 500 Power 
Supply, Biorad Laboratories) and adjust voltage 50, 
mAmps to 56. 
14. Run for 2.5 hours. 
15. Dissemle transfer unit. Mark the edges of the 
nitrocellulose according to the top, bottom and sides of 
the gel. Cut off the standard lane and adjacent protein 
lane with sharp razor blade. Nick the bottom right-hand 
corner of each. Label both the standard and protein 
nitrocellulose sheets with gel #/identity. Wash the 
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standard nitrocellulose sheet with PBS then dH20 and 
then place in Aurodye for resolution of protein standards 
as well as membrane protein resolution. Place the 
protein nitrocellulose sheet in blocking solution in 
preparation for the immunoblot procedure. 
c. lmmunoblot 
1. Procedure A: (Alkaline Phosphatase) 
a. Block nitrocellulose paper in 1 °/o BSA/PBS for a 
minimum of 2 hours at room temperature. 
b. Wash each nitrocellulose paper in individual troughs 
with PBS/0.05°/o tween 20, 3 times for 5-10 minute·s, 
each wash, under agitation. Blot. 
c. Assemble nitrocellulose, face side up, in 
Miniblotter 16 apparatus, (lmmunetics, Cambridg_e, 
MA.) and place a blotter paper behind each 
nitrocellulose paper. Screw bottom of the 
Miniblotter 16 on tightly. 
d. Pipette 130ul of specific antibody dilution or PBS 
(-primary control) into individual, alternating lanes. 
e. Incubate at 37'C for 1-1.5 hours. 
f. Wash lanes with 50 mis. PBS/0.05°/o tween 20 using 
vacuum filter device. 
g. Dissemble immunoblotter and wash nitrocellulose 
papers in individual troughs with PBS/0.05°/o tween20, 
3 times, 5-10 minutes each under agitation. 
h. Blot. Put nitrocellulose papers in individual petrie 
dishes and add 5 mis. of secondary antibody ( a 1:1000 
dilution of goat antimouse lgG/Alkaline phosphatase 
conjugate in PBS), to each oish. 
i. Cover incubate room temperature 30 minutes. 
j. Wash as stated above in step g. 
k. Blot. Remove nftrcellulose papers to clean dishes and 
add substate, (NBT/BCI P). 
I. Allow color development to continue until desired 
intensity. is reached. Stop the reaction by washing 
nitrocellulose with dH20. 
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2. Procedure B: ( Horse Radish Peroxidase) 
a. Block nitrocellulose in solution of 5°/o nonfat dry milk 
in PBS, which had been heated to 65'C for 1 hour prior 
to use, for 1 hour at 37'C. 
b. Wash nitrocellulose briefly 2-3 times with 
PBS/tween 20, approximately 10 mls./wash. 
c. Assemble immunoblotter apparatus as descibed in 
Procedure A. 
d. Pipette 130ul of antibody dilution or PBS in 
individual, alternating lanes. 
e. Incubate 1-1.5 hours. 
f. Wash lanes with 50 mis. PBS/0.05°/o tween 20 using 
vacuum filter device. 
g. Dissemble immunoblotter and wash nitrocellulose 
papers in individual troughs with PBS/0.05°/o tween20, 
3 times, 5-1 O minutes each, under agitation. 
h. Blot. Put nitrocellulose papers in individual petrie 
dishes and add 5 mis. of secondary antibody, ( 1 :2000 
dilution of goat anti-mouse lgG/HRP conjugate. in PBS) 
to each dish. 
i. Cover and incubate at 37'C for 1 hour. 
j. Wash as stated above in step g. 
k. Wash an adqitional 2 times in PBS; this final wash is 
important as tween 20 inhibits the reaction of 
peroxidase with the 181 enzymatic web, 
(International Biotechnologies, Inc.) 
I. Blot. -Remove nitrocellulose papers to clean dry 
surface with the probed surface facing up. 
m. Lay the frosted surface of the 181 enzymatic web,(on 
top of the blot. Rub with sufficient pressure to 
create an even,, intimate contact with the web. 
n. The target will appear rapidly on the web, within 
seconds to minutes. 
o. Photograph promptly or store at -70'C. 
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RADIOIODINATION OF HCG 
Materials 
1) Gelatin Buffer ( pH 7.4) 
- NaP04 
- NaCl 
0.05M 
0.05M 
- Gelatin 0.1 °/o 
*Note: Microwave. and cool before use. 
2) 0.05M P04 (total volume 200 mis; pH 7.25) 
- NaP04 (monobasic) 0.311g 
- NaP04 (dibasic) 1.098g 
3) 0.5M P04 ( total volume 200 mis; pH 7~25) 
- NaP04 (monobasic) 3.11g 
~ NaPo4 (dibasic) 10.98g 
4) H202 (final concentration; 1 :80,000) 
- H202 20ul(1 :400 stock)/4 mis dH20 
5) Lactoperoxidase Solution 
- Lactoperoxidase 
6) Transfer Solution 
- NaP04 
- Sucrose 
- NaN3 
0. 1 mg/ml O.OSM NaP04 
0.05M 
8°/o· 
0.6°/o 
7) 4°/o BSA/Gelatin Buffer Solution (total volume 100 mis) 
- BSA 4g/100 mis gelatin buffer 
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Procedure 
1. Prepare a 1 O ml. G-25 column in gelatin buffer with 0.1 mg/ml 
trypsin inhibitor. 
2. To a microfuge tube add 15 ug of hCG, (15 ul of a 1 mg/ml stock 
in 0.05 M P04). The hCG used is NIH CR-127, ultrapure quality. 
3. Add 25 ul of 0.5 M P04. 
4. Add 1 O ul freshly diluted H202. 
5. Add 20 ul Nal, (approximately 2mCi). 
6. To start the reaction, add 10 ul lactoperoxidase solution, 
(approximately 1 ug of protein). Mix well. 
7. Incubate 3-4 minutes at 4'C. 
8. Stop reaction by adding 100 ul of transfer solution. 
9. Drain column down to the bed volume. 
10. Precoat transfer pipette with 4°/o BSA/gelatin buffer solution 
and rinse with gelatin buffer. 
11. Transfer hCG mixture to the top of the G-25 column and drain 
sample into beads. 
12. Collect 1 ml alloquots into 12 X 75 glass tubes, adding 1 ml 
alloquots to the top of the column during fraction collection 
procedure. 
13. Measure radioactivity in each fraction. 
14. Pool fractions containing *l-125 hCG, approximately 3 mis. 
15. Adq equal volume, approximately 3 mis. of 4°/o BSA/gelatin 
buffer. 
16. Dialyze against PBS, pH 7.4. 
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I was born in Paterson, New Jersey on October 22, 1960; the second of five 
children born to Joseph and Ann Hilton. The first 8 years of my life were spent in 
Wayne, New Jersey, before .moving to Bethlehem, Pennsylvania in July; 1968. 
I attended high school at St. Francis Academy, Bethlehem, Pa., and during my 
four years there was actively involved in many diverse activities. These included singing 
second soprano in the glee club, playing the violin in the. school orchestra, bei°ng a 
member of the Legion of Mary, as well as being the starting center/forward on the 
basketball team. I served as class secretary in my junior .year and as class president in 
my senior year. While at St. Francis I maintained a 4.0 gra_de point average, was a 
member of the National Honor Society, and was selected for the Who's Who Among 
American High School Students. Summers of my freshman and sophomore years I had the 
opportunity to tour abroad, traveling throughout Italy and the British Isles, 
respectively. Upon graduation from St. Francis I was awarded the John O'Boyle 
Basketball Memorial Award for my achievement in the spqrt. 
I attended lmmaculata College and East Stroudsburg State University where I 
majored in. Biology. During college I was also actively involved in sports; playing field 
hockey, softball and a forward/center position on the starting basketball team, for 
which I received the All-Conference, All-Tournament and Most Valuable Player Awards. 
I graduated from college ·in 1982 with a B.S Degree in Biology, graduating Summa Cum 
Laude with a grade. point average o.f 3.95. I was a member of the Sigma Zeta Honorary 
Science .Society and upon graduation wa~ presented with an award for outstanding 
academic achievement in Biology. 
o.c. 
I was ~epted into the Allentown Hospital School of Medical Technology, a 
12-month internship spent in both intense academic training and clinical laboratory 
rotation. While at Allentown Hospital I was a student employee in the Microbiology 
department and was a member of Student Bowl Team, competing in York, Pa. Upon 
graduation I was presented with the award for the highest academic achievement. I am ·a 
certified Medical Technologist, (American Society of Clinical Pathologists; A.S.-C.P .), 
successfully completing the National Board of Registry Examinations. 
My experience as a medical technologist includes all areas of clinical 
laboratory work and phlebotomy ,(Muhlenberg Hospital Center); microbiology 
• (St.Luke's Hospital) in which, as sole technologist on second shift was responsible for 
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all facets of clinical microbiolo.gy work; and in vitro fertilization (St. Luke's Hospital) 
in which my responsibilites included clinical testing in andrology and reproductive 
immunology as well as assitance in the embryo lab adjacent to the operating room during 
oocyte retrievals, G.I.F.T. ,and IVF-ET surgical procedures. 
My interest in reproductive endocrinolgy and embryology lead me to pursue 
further training in this area, and as such was able to make the necessary arrangements 
to spend 5 months working in the In Vitro Fertilization program at Harvard Medical 
School/ Brigham and Women's Hospital in Boston, Ma., in the Fall of 1987, under the 
direction of Dr. Ann Kiessling. While in Boston I had the opportunity to get first hand 
experience in human embryo culturing and .gamete/ embryo transfer. I was responsible 
for all of the quality control for the program; this involved the hyperstimulation and 
mating of female BDF mice as well as the retrieval and culturing of 1-cell mouse 
embryos. I was also involved in a personal research project investigating an embryonic 
2-cell block caused by hypoxanthine, in specific strains of mice. Of special enjoyment to 
me was the opportunity to attend fascinating seminars and conferences in reproductive 
biology during my stay there, and was able to return to Boston the following February in 
order to attend the national meetings of Science; the specific 3-day conference in 
Reproductive Biology which I° attended being sponsored by the Harvard Group which I had 
been affiliated with. 
I returned to school full-time in the fall of 1988, to Lehigh University 
wh.ere I am currently a graduate student in the Molecular Biology Department. For the 
past two years I have also taught a clinical mic_robiology lab course at the St. Luke,.s 
School of Nursing; a program affilitated with Pennsylvania State University. Upon 
completion of my Master's. degree I hope to continue my academic/research training in 
.order to successfully earn a Doctorate degree. 
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